PatientID,TrialID,TrialTitle,Sponsor,Age,Gender,Ethnicity,Region,BiomarkerStatus,DiseaseStage,TreatmentArm,Outcome
P-10001,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,62,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10002,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,73,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10003,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10004,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,39,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10005,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,71,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-10006,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,66,Female,White,Europe,HER2+,Stage I,Control,Responder
P-10007,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,63,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-10008,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10009,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,50,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10010,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,65,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-10011,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,55,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-10012,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,31,Female,Black/African American,North America,HER2+,Stage III,Experimental,Responder
P-10013,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,69,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10014,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,43,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10015,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,69,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10016,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,54,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10017,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,47,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-10018,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,55,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Non-Responder
P-10019,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,49,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10020,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,54,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-10021,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,49,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10022,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10023,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,41,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10024,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10025,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,72,Male,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10026,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,25,Female,Other,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10027,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10028,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,64,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10029,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,62,Female,White,North America,TNBC,Stage III,Control,Responder
P-10030,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,78,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10031,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10032,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,65,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10033,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,52,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10034,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,41,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10035,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,66,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10036,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,66,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10037,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,55,Female,Other,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10038,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,80,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10039,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,67,Female,Hispanic/Latino,Europe,HER2+,Stage II,Control,Responder
P-10040,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,42,Female,White,Europe,TNBC,Stage II,Control,Responder
P-10041,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,61,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10042,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,74,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10043,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,68,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-10044,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,52,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10045,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,69,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10046,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,67,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10047,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10048,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,36,Female,Other,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10049,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10050,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10051,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,76,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10052,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,71,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10053,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,79,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-10054,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,54,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-10055,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,46,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10056,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10057,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,54,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10058,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,56,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10059,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,76,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10060,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10061,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,51,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10062,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,48,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10063,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,Asian,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10064,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,42,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Responder
P-10065,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,31,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10066,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,37,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-10067,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,57,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10068,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,39,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-10069,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,70,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10070,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,48,Female,Black/African American,North America,HER2+,Stage III,Experimental,Responder
P-10071,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,65,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10072,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,40,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-10073,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,41,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10074,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10075,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,64,Female,White,Europe,HR+/HER2+,Stage I,Control,Non-Responder
P-10076,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,69,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-10077,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,68,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10078,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,50,Female,White,Europe,TNBC,Stage II,Control,Responder
P-10079,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,53,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10080,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,66,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10081,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,39,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10082,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,76,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-10083,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,72,Female,Other,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10084,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10085,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10086,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,38,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-10087,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,40,Female,White,North America,HR+/HER2+,Stage III,Experimental,Responder
P-10088,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,47,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10089,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,63,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10090,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,71,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10091,NCT01075100,Ixabepilone + Carboplatin Metastatic Breast Cancer,US Oncology Research,74,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10092,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10093,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",74,Female,Other,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10094,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",61,Female,Hispanic/Latino,North America,HER2+,Stage II,Control,Non-Responder
P-10095,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",57,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Responder
P-10096,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",54,Female,White,Asia-Pacific,TNBC,Stage I,Control,Responder
P-10097,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10098,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",71,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-10099,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10100,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10101,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",50,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-10102,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",38,Female,White,North America,TNBC,Stage III,Control,Responder
P-10103,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",75,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10104,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",37,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10105,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10106,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",58,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage I,Experimental,Responder
P-10107,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",40,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10108,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10109,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",71,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10110,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",70,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10111,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",62,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10112,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",45,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10113,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10114,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",60,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-10115,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",43,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10116,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",60,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10117,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",72,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10118,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",68,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-10119,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",48,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10120,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",53,Female,Black/African American,North America,TNBC,Stage III,Control,Responder
P-10121,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",66,Female,Black/African American,Europe,HER2+,Stage III,Control,Responder
P-10122,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",54,Female,White,Europe,HER2+,Stage II,Control,Responder
P-10123,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",56,Female,Asian,Europe,HER2+,Stage II,Experimental,Non-Responder
P-10124,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10125,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Male,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10126,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",58,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10127,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",43,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10128,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-10129,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10130,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",70,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-10131,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10132,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",71,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10133,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10134,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",72,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10135,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",54,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-10136,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",48,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10137,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10138,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",47,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10139,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",60,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10140,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10141,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",65,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10142,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",47,Female,Hispanic/Latino,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10143,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",51,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10144,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",65,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10145,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",45,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10146,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10147,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",72,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10148,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",69,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-10149,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-10150,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",69,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10151,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",38,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-10152,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10153,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",54,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10154,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",54,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10155,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",72,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10156,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",38,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-10157,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",86,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10158,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",76,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10159,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10160,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10161,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",42,Female,White,Latin America,HER2+,Stage I,Control,Non-Responder
P-10162,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",56,Female,Asian,North America,HER2+,Stage I,Control,Responder
P-10163,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",77,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10164,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",61,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10165,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",68,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-10166,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",64,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Experimental,Responder
P-10167,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",80,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10168,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",68,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10169,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-10170,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",66,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10171,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",74,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Responder
P-10172,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",52,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10173,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",67,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Responder
P-10174,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10175,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",63,Female,White,North America,TNBC,Stage III,Control,Responder
P-10176,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",42,Female,Asian,Europe,TNBC,Stage I,Experimental,Responder
P-10177,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",59,Female,Other,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10178,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10179,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",73,Female,White,Asia-Pacific,HER2+,Stage I,Control,Non-Responder
P-10180,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",53,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10181,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",71,Female,White,Asia-Pacific,TNBC,Stage III,Control,Responder
P-10182,NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",53,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10183,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,44,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-10184,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,49,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10185,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,72,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-10186,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,66,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10187,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-10188,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,77,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10189,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10190,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,74,Female,White,Latin America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-10191,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10192,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,77,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10193,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-10194,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10195,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,74,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10196,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,62,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10197,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,78,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-10198,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10199,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-10200,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,29,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10201,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,31,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10202,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,73,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10203,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10204,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,68,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10205,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,52,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10206,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,68,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10207,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-10208,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,82,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-10209,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,75,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10210,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,60,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10211,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-10212,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,77,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Responder
P-10213,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,58,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-10214,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10215,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10216,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-10217,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10218,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,53,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10219,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,42,Female,Black/African American,Europe,HER2+,Stage III,Control,Responder
P-10220,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,73,Male,White,North America,HER2+,Stage I,Experimental,Responder
P-10221,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,61,Female,White,North America,HR+/HER2+,Stage III,Experimental,Responder
P-10222,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,82,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10223,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10224,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10225,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,49,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10226,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,46,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10227,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10228,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,33,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10229,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,54,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10230,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10231,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,52,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-10232,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,60,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10233,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,52,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10234,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,46,Female,Asian,Europe,HER2+,Stage II,Experimental,Responder
P-10235,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,80,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10236,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,65,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10237,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,53,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-10238,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,70,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10239,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,58,Female,Other,Europe,TNBC,Stage II,Experimental,Responder
P-10240,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,59,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10241,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10242,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10243,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,69,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10244,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10245,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,50,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10246,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,46,Female,Black/African American,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-10247,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,84,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10248,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,27,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10249,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10250,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,49,Female,White,Asia-Pacific,TNBC,Stage I,Experimental,Responder
P-10251,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10252,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,34,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-10253,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,46,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10254,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,74,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-10255,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Male,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10256,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,65,Male,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10257,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,68,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10258,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,54,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10259,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10260,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,71,Female,Black/African American,North America,HR+/HER2+,Stage II,Experimental,Responder
P-10261,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,63,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10262,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,76,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10263,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,71,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10264,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10265,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,61,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-10266,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,53,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10267,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,56,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10268,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,65,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10269,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,57,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10270,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,52,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10271,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,84,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10272,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10273,NCT03372902,Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening,Memorial Sloan Kettering Cancer Center,47,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10274,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,52,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10275,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,46,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10276,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,90,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10277,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,63,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10278,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,56,Female,Black/African American,North America,HER2+,Stage I,Experimental,Non-Responder
P-10279,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,59,Male,Black/African American,North America,HR+/HER2-,Stage I,Control,Responder
P-10280,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,73,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10281,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,59,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10282,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,29,Female,White,North America,TNBC,Stage I,Control,Non-Responder
P-10283,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,62,Female,White,Latin America,HR+/HER2-,Stage I,Control,Non-Responder
P-10284,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,70,Female,White,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-10285,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,62,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10286,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,56,Female,Asian,North America,HER2+,Stage III,Control,Non-Responder
P-10287,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,25,Female,Black/African American,North America,HR+/HER2+,Stage II,Control,Responder
P-10288,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,71,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10289,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,48,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10290,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,42,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10291,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,44,Female,Asian,North America,HER2+,Stage II,Control,Non-Responder
P-10292,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,45,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-10293,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,58,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-10294,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,64,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Non-Responder
P-10295,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,60,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10296,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,62,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10297,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,34,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10298,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10299,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,58,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-10300,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,65,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-10301,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,66,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10302,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,65,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10303,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,73,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-10304,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,65,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-10305,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,66,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10306,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,43,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10307,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,47,Female,White,Europe,HER2+,Stage II,Control,Responder
P-10308,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,56,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10309,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,73,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10310,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,71,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10311,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10312,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,50,Female,White,North America,HER2+,Stage III,Control,Responder
P-10313,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-10314,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,48,Female,White,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-10315,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,41,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10316,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,88,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Control,Responder
P-10317,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,56,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10318,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,79,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10319,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,63,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-10320,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-10321,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,50,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10322,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,50,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10323,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,52,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10324,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,85,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-10325,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,65,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10326,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,47,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10327,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,70,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10328,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,59,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-10329,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,61,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10330,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,76,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10331,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,71,Male,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10332,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,72,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10333,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,60,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10334,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10335,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,40,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10336,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,43,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10337,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10338,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,79,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10339,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,Black/African American,North America,TNBC,Stage III,Control,Responder
P-10340,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,69,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10341,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,69,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10342,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10343,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,45,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10344,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,57,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-10345,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10346,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,55,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10347,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,53,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10348,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,38,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10349,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,45,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10350,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,58,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10351,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,62,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10352,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10353,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,72,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10354,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10355,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,45,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10356,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,87,Female,Asian,Asia-Pacific,TNBC,Stage II,Control,Responder
P-10357,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,51,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10358,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,49,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10359,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10360,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,68,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10361,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,61,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10362,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,49,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10363,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,47,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10364,NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,Emory University,74,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10365,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,41,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10366,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10367,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,69,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10368,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,67,Female,Black/African American,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10369,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,28,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10370,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,45,Female,Asian,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-10371,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,42,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10372,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,39,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10373,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,49,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10374,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,47,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10375,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,63,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10376,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10377,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,56,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10378,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10379,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,64,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10380,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,36,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-10381,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,32,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10382,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10383,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,54,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10384,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,71,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10385,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,36,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10386,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10387,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,44,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10388,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,63,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10389,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,69,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10390,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10391,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,54,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10392,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,57,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10393,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,69,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-10394,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,60,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10395,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,85,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10396,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10397,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,66,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10398,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,61,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10399,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,57,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10400,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,79,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10401,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,62,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10402,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,69,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Responder
P-10403,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10404,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,56,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10405,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,61,Female,White,Asia-Pacific,TNBC,Stage III,Control,Responder
P-10406,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,53,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-10407,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,77,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10408,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10409,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,68,Female,Black/African American,Europe,HER2+,Stage I,Experimental,Responder
P-10410,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,77,Female,Other,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10411,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,54,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-10412,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10413,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,71,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-10414,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,48,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-10415,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,62,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10416,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,84,Female,White,Latin America,TNBC,Stage III,Control,Non-Responder
P-10417,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,81,Female,Black/African American,Latin America,HER2+,Stage IV (Metastatic),Control,Responder
P-10418,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,51,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10419,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,56,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10420,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,42,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10421,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,89,Female,Asian,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-10422,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,39,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10423,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10424,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,61,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10425,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,73,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10426,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10427,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10428,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,32,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10429,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,71,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10430,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10431,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,90,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10432,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,90,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-10433,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,74,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10434,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,64,Female,White,Asia-Pacific,TNBC,Stage I,Control,Responder
P-10435,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,52,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-10436,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,53,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10437,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,69,Female,White,Latin America,TNBC,Stage III,Experimental,Responder
P-10438,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,32,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10439,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,72,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10440,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10441,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10442,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,31,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10443,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,47,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10444,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,50,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10445,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,47,Female,Asian,North America,HER2+,Stage I,Control,Non-Responder
P-10446,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,78,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10447,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,72,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10448,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10449,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10450,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,58,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-10451,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,77,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10452,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,37,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-10453,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,50,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-10454,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,50,Female,White,Europe,HR+/HER2+,Stage I,Experimental,Responder
P-10455,NCT03912948,Chronic Pain and Minor Breast Cancer Surgery,Institut Claudius Regaud,52,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10456,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10457,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,64,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10458,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-10459,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,57,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-10460,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,32,Female,White,Asia-Pacific,HER2+,Stage III,Control,Responder
P-10461,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,59,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10462,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,55,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10463,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,69,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-10464,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10465,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-10466,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10467,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10468,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,51,Female,White,Latin America,HR+/HER2-,Stage I,Control,Non-Responder
P-10469,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,59,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10470,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,90,Female,Hispanic/Latino,North America,TNBC,Stage III,Control,Non-Responder
P-10471,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,65,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10472,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,48,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Control,Responder
P-10473,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,61,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10474,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,58,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10475,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,34,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10476,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,51,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10477,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,46,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-10478,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10479,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,51,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10480,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,50,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-10481,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10482,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,78,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10483,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,75,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-10484,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,38,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10485,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,61,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10486,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10487,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,56,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10488,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,40,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-10489,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10490,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,67,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-10491,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,75,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10492,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,62,Female,Other,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10493,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-10494,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,34,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10495,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,70,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10496,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,80,Female,Hispanic/Latino,North America,TNBC,Stage III,Control,Non-Responder
P-10497,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,62,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10498,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,62,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10499,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10500,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,37,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-10501,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,57,Female,Hispanic/Latino,Europe,TNBC,Stage II,Experimental,Responder
P-10502,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,71,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10503,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,48,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10504,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,73,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Responder
P-10505,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,49,Female,White,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-10506,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10507,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,72,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10508,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,54,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10509,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,58,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10510,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10511,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,44,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10512,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,69,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10513,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10514,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,71,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10515,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,62,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10516,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,31,Female,Black/African American,North America,HER2+,Stage III,Control,Non-Responder
P-10517,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,47,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10518,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,55,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10519,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,48,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10520,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10521,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,59,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10522,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,71,Female,White,Latin America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10523,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10524,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,38,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-10525,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,68,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-10526,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,50,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-10527,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,45,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10528,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,71,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10529,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10530,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10531,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10532,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,50,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10533,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,39,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10534,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,61,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10535,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,76,Female,Asian,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-10536,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,60,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10537,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,65,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10538,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,55,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10539,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,47,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10540,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,48,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10541,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,75,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10542,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10543,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,65,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10544,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,49,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-10545,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,75,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10546,NCT04117815,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,Medical University Innsbruck,62,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-10547,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,52,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10548,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10549,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,50,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-10550,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,75,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10551,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,44,Female,Other,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10552,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,52,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10553,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10554,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,59,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10555,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,53,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10556,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10557,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,71,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10558,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10559,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,59,Female,White,Latin America,TNBC,Stage III,Control,Responder
P-10560,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,44,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10561,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,59,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10562,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,73,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10563,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,55,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-10564,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,55,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Responder
P-10565,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,62,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-10566,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,75,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-10567,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,67,Female,White,Asia-Pacific,TNBC,Stage I,Experimental,Responder
P-10568,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,54,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10569,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,76,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10570,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10571,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,52,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-10572,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,74,Female,Hispanic/Latino,Europe,TNBC,Stage III,Control,Non-Responder
P-10573,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,71,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10574,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10575,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,74,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10576,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10577,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,65,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10578,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,53,Female,White,Europe,HER2+,Stage III,Control,Responder
P-10579,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,51,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10580,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,53,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-10581,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,72,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10582,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,43,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10583,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,55,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10584,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,44,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10585,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,83,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10586,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-10587,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,48,Female,Other,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10588,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10589,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,37,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10590,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10591,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,47,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10592,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,65,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Control,Non-Responder
P-10593,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,38,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10594,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,57,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10595,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,60,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-10596,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,52,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Control,Responder
P-10597,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,35,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10598,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10599,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,33,Female,White,Europe,TNBC,Stage II,Control,Responder
P-10600,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,62,Female,White,North America,TNBC,Stage III,Control,Responder
P-10601,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,42,Female,Hispanic/Latino,North America,TNBC,Stage I,Control,Non-Responder
P-10602,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,46,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10603,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,69,Female,Hispanic/Latino,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-10604,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,48,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10605,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,58,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10606,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10607,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,61,Female,Hispanic/Latino,North America,TNBC,Stage II,Control,Non-Responder
P-10608,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,58,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-10609,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,49,Female,White,Latin America,TNBC,Stage III,Control,Responder
P-10610,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10611,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,40,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10612,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,62,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10613,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10614,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,77,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10615,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,46,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10616,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,64,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10617,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,64,Female,Other,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10618,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,51,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-10619,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,Hispanic/Latino,North America,TNBC,Stage II,Control,Responder
P-10620,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,50,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10621,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,63,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10622,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10623,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,57,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage I,Experimental,Responder
P-10624,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,53,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage I,Experimental,Responder
P-10625,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10626,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,69,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10627,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,45,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10628,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,58,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10629,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,76,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10630,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,49,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10631,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,49,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10632,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,70,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-10633,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10634,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,56,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10635,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,49,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-10636,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10637,NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,Cancer Research Campaign Clinical Trials Centre,56,Female,Asian,North America,TNBC,Stage II,Experimental,Responder
P-10638,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,77,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10639,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,74,Female,Black/African American,Europe,HER2+,Stage I,Experimental,Non-Responder
P-10640,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,62,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10641,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,25,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-10642,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10643,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,43,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10644,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,57,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-10645,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,58,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10646,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,53,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10647,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,40,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10648,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,56,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10649,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,72,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10650,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,73,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10651,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,71,Female,White,Europe,TNBC,Stage II,Control,Responder
P-10652,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,40,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10653,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,61,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10654,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,55,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10655,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,63,Female,White,Asia-Pacific,HER2+,Stage II,Control,Responder
P-10656,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10657,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,32,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10658,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,65,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10659,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,42,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10660,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,Hispanic/Latino,North America,TNBC,Stage II,Control,Responder
P-10661,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,34,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10662,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,69,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-10663,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,74,Female,Black/African American,North America,HR+/HER2+,Stage II,Control,Responder
P-10664,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,51,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10665,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10666,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,64,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10667,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,65,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-10668,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,68,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10669,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,55,Female,White,North America,TNBC,Stage III,Control,Responder
P-10670,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10671,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,35,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10672,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10673,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,78,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10674,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,66,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10675,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10676,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,52,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10677,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10678,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,72,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10679,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,62,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-10680,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,40,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10681,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,67,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10682,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,54,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10683,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,45,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-10684,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,69,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10685,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,57,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Responder
P-10686,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,79,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10687,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,57,Male,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10688,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,74,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-10689,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,80,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10690,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10691,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,74,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10692,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10693,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,61,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-10694,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10695,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,55,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10696,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,83,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10697,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,56,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-10698,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,64,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-10699,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,38,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10700,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,47,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10701,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,85,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10702,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,49,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10703,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,56,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10704,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,60,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10705,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,73,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10706,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,84,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-10707,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,72,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10708,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,28,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10709,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-10710,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,59,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10711,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,48,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10712,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,67,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-10713,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,64,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-10714,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,61,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10715,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,68,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10716,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,56,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-10717,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,57,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10718,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,68,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-10719,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,55,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10720,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,56,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10721,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,62,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10722,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,65,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10723,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,39,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10724,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,48,Female,White,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-10725,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,87,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10726,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,38,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-10727,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,47,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10728,NCT01317108,Prognostic and Predictive Impact of uPA/PAI-1,Universittsklinikum Hamburg-Eppendorf,54,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10729,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",62,Female,Asian,Europe,TNBC,Stage I,Control,Responder
P-10730,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",57,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10731,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",76,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Control,Responder
P-10732,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",74,Female,White,Latin America,TNBC,Stage IV (Metastatic),Control,Responder
P-10733,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",38,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10734,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",62,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-10735,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",25,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-10736,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",26,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-10737,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",48,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10738,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",57,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10739,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10740,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",58,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10741,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",63,Female,Black/African American,North America,TNBC,Stage III,Experimental,Non-Responder
P-10742,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",57,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-10743,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",69,Female,White,Latin America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10744,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",56,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-10745,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",55,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10746,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10747,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",68,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10748,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",74,Female,Black/African American,Asia-Pacific,HR+/HER2+,Stage I,Experimental,Responder
P-10749,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",58,Female,Asian,Europe,HER2+,Stage II,Control,Responder
P-10750,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",72,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10751,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",47,Female,White,North America,HR+/HER2+,Stage I,Experimental,Responder
P-10752,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",55,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-10753,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",36,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10754,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",47,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10755,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",42,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-10756,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",72,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10757,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",48,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10758,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",48,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10759,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",78,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10760,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",46,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-10761,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",68,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10762,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",59,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-10763,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",34,Female,White,Latin America,TNBC,Stage III,Control,Non-Responder
P-10764,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",59,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-10765,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",74,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10766,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10767,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",66,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10768,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",67,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10769,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",57,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-10770,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",62,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10771,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",80,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10772,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",75,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10773,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",75,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10774,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",56,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-10775,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10776,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10777,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",46,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10778,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",52,Female,Hispanic/Latino,Europe,TNBC,Stage II,Control,Non-Responder
P-10779,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10780,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10781,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",71,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10782,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",54,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10783,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",65,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-10784,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",49,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-10785,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",75,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10786,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",58,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-10787,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",58,Female,Black/African American,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-10788,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",81,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-10789,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10790,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",50,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-10791,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",53,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-10792,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",40,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-10793,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",64,Female,White,Europe,HR+/HER2+,Stage III,Control,Non-Responder
P-10794,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",63,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10795,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,White,Latin America,TNBC,Stage IV (Metastatic),Control,Responder
P-10796,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",78,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-10797,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",53,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10798,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",35,Female,Asian,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-10799,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",71,Female,White,North America,HER2+,Stage III,Control,Responder
P-10800,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",69,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-10801,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",46,Female,Black/African American,North America,TNBC,Stage III,Experimental,Non-Responder
P-10802,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10803,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",48,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10804,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",65,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-10805,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",49,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10806,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",33,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-10807,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",49,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10808,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",44,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10809,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10810,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",25,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10811,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",30,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10812,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",60,Female,White,Europe,HR+/HER2+,Stage III,Control,Non-Responder
P-10813,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,Asian,North America,TNBC,Stage I,Control,Non-Responder
P-10814,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",48,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10815,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",65,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10816,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",65,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10817,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-10818,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",66,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10819,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,"University of Colorado, Denver",45,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10820,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,71,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10821,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,34,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10822,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,59,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-10823,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10824,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,62,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10825,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,60,Female,Asian,Europe,TNBC,Stage III,Control,Responder
P-10826,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,63,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-10827,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,55,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10828,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,52,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10829,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,47,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-10830,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10831,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,58,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10832,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,73,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10833,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,62,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10834,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10835,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,55,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10836,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,39,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10837,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,59,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10838,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,78,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10839,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,58,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10840,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10841,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,70,Female,Other,North America,HR+/HER2+,Stage III,Control,Responder
P-10842,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,41,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10843,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10844,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,60,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-10845,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,37,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10846,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10847,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,64,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-10848,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,56,Female,Black/African American,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-10849,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,55,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-10850,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-10851,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10852,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,Asian,North America,HER2+,Stage II,Experimental,Responder
P-10853,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,56,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-10854,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,42,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10855,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,42,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10856,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,72,Female,Black/African American,Europe,TNBC,Stage III,Control,Non-Responder
P-10857,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,70,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10858,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,30,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10859,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,64,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10860,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10861,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,61,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10862,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,66,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10863,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10864,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,76,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10865,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,44,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10866,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10867,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10868,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,37,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10869,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,74,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10870,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,57,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10871,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10872,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,52,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10873,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,42,Female,Asian,North America,HER2+,Stage I,Experimental,Responder
P-10874,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,38,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10875,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,64,Female,White,North America,HR+/HER2+,Stage III,Experimental,Responder
P-10876,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,48,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10877,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,76,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10878,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,76,Female,Asian,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10879,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,40,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10880,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,66,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-10881,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,74,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10882,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10883,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,61,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10884,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,82,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10885,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,64,Female,White,North America,TNBC,Stage III,Control,Responder
P-10886,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,46,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10887,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,58,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10888,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,56,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-10889,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,White,Europe,HER2+,Stage III,Control,Responder
P-10890,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10891,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,60,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Responder
P-10892,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,29,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-10893,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,55,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10894,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,48,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10895,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,46,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-10896,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10897,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10898,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,74,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10899,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,34,Female,Hispanic/Latino,Europe,TNBC,Stage II,Control,Non-Responder
P-10900,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,60,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10901,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,53,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10902,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10903,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,74,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10904,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10905,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,52,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10906,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10907,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10908,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,78,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10909,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,60,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10910,NCT00972413,Cone Beam Computed Tomography for Breast Imaging,Koning Corporation,59,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-10911,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,41,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10912,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10913,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10914,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,41,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-10915,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,60,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-10916,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10917,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,40,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10918,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,75,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10919,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,52,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-10920,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,63,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10921,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,55,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10922,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10923,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,47,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10924,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,59,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-10925,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,67,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-10926,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10927,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,70,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10928,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,68,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10929,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,57,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Non-Responder
P-10930,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,69,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-10931,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,53,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-10932,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,60,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-10933,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,57,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10934,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,53,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-10935,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10936,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,46,Female,Other,Latin America,HER2+,Stage II,Experimental,Responder
P-10937,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,76,Female,White,Europe,TNBC,Stage II,Control,Responder
P-10938,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,Hispanic/Latino,North America,TNBC,Stage I,Control,Responder
P-10939,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10940,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,64,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-10941,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,57,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10942,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,72,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-10943,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,63,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10944,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,40,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10945,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,80,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-10946,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,62,Female,Other,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10947,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10948,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,66,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10949,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,62,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10950,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,67,Female,Black/African American,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-10951,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,61,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-10952,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,59,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-10953,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,52,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10954,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,59,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10955,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,54,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10956,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,60,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10957,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,73,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10958,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,40,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10959,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,41,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-10960,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,49,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-10961,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,63,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-10962,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,66,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10963,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,39,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-10964,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,54,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10965,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,53,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10966,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,50,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10967,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-10968,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-10969,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,62,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10970,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,50,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-10971,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,62,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10972,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,61,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-10973,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,48,Female,Asian,North America,HER2+,Stage III,Experimental,Responder
P-10974,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,67,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-10975,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,68,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10976,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,54,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-10977,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,63,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-10978,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,77,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-10979,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-10980,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,25,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10981,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,45,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-10982,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,80,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10983,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-10984,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,46,Female,Asian,North America,TNBC,Stage I,Experimental,Non-Responder
P-10985,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,47,Female,White,North America,HER2+,Stage I,Control,Responder
P-10986,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,51,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10987,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,68,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-10988,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,49,Female,White,Europe,HR+/HER2+,Stage I,Control,Non-Responder
P-10989,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,71,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-10990,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10991,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,50,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-10992,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,53,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-10993,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,35,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-10994,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-10995,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,39,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-10996,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,61,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-10997,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,60,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-10998,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,65,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-10999,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,45,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11000,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,50,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-11001,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Universidad Nacional de Colombia,78,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11002,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",44,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11003,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",54,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11004,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",50,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11005,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",48,Female,Asian,Europe,HER2+,Stage III,Control,Responder
P-11006,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,Europe,HER2+,Stage III,Control,Responder
P-11007,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",47,Female,Black/African American,Europe,TNBC,Stage III,Control,Responder
P-11008,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11009,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11010,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11011,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,Other,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11012,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",44,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-11013,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",65,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11014,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",56,Female,Black/African American,Europe,TNBC,Stage I,Control,Responder
P-11015,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",58,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Responder
P-11016,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",52,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11017,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,White,Europe,TNBC,Stage I,Experimental,Responder
P-11018,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",51,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11019,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",76,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11020,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",72,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11021,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",74,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11022,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",67,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11023,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",70,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-11024,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",85,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11025,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",53,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-11026,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",56,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11027,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",69,Female,Black/African American,North America,TNBC,Stage I,Control,Non-Responder
P-11028,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",50,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11029,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",60,Female,Other,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11030,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",30,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11031,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",66,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-11032,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",45,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11033,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",46,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11034,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",51,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11035,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11036,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",50,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-11037,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",53,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11038,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",66,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11039,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",55,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11040,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",75,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11041,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11042,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",59,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11043,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11044,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",79,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11045,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",77,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11046,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",60,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-11047,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11048,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",34,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11049,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",78,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11050,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",60,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11051,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",62,Female,White,Europe,TNBC,Stage III,Control,Responder
P-11052,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",32,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11053,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",44,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11054,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",41,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11055,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11056,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-11057,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11058,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11059,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",33,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11060,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11061,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",73,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11062,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",59,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-11063,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11064,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,White,Latin America,TNBC,Stage II,Experimental,Non-Responder
P-11065,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",56,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11066,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",41,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11067,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",74,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11068,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",80,Female,White,North America,HER2+,Stage II,Control,Responder
P-11069,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",56,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11070,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",71,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11071,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",49,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11072,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",35,Female,Black/African American,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-11073,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",45,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11074,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",57,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-11075,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11076,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",67,Female,Asian,North America,TNBC,Stage II,Experimental,Non-Responder
P-11077,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",58,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11078,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",39,Female,White,North America,HER2+,Stage I,Control,Responder
P-11079,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",44,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-11080,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",47,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11081,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",57,Female,White,Europe,HER2+,Stage III,Control,Responder
P-11082,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",61,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11083,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",43,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11084,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",50,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-11085,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",66,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11086,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11087,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",39,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11088,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",45,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11089,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",71,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11090,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",46,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11091,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",35,Female,Asian,North America,TNBC,Stage III,Control,Responder
P-11092,NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,"First Affiliated Hospital, Sun Yat-Sen University",54,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11093,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,59,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11094,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,69,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11095,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11096,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11097,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,41,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11098,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,68,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11099,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,55,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11100,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,68,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11101,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,73,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11102,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,44,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11103,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,43,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11104,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,38,Female,Other,Europe,HER2+,Stage II,Experimental,Non-Responder
P-11105,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11106,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,46,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11107,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,68,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-11108,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11109,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,27,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11110,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,48,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-11111,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,75,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11112,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,73,Female,Other,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11113,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,29,Female,Black/African American,Europe,HER2+,Stage I,Control,Non-Responder
P-11114,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,65,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11115,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11116,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,67,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-11117,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,63,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11118,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11119,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,82,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11120,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,67,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11121,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,52,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-11122,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,56,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11123,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11124,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,53,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-11125,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,66,Female,Other,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-11126,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,25,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11127,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,64,Female,Other,Europe,HR+/HER2-,Stage I,Control,Responder
P-11128,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-11129,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,49,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11130,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,52,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Experimental,Responder
P-11131,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Male,Hispanic/Latino,Europe,HER2+,Stage III,Experimental,Non-Responder
P-11132,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,72,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11133,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11134,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11135,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,69,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11136,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,71,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11137,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,67,Female,White,Europe,HER2+,Stage II,Control,Responder
P-11138,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,72,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11139,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,43,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage I,Experimental,Non-Responder
P-11140,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,41,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-11141,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11142,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,71,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11143,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,35,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11144,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,47,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11145,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,84,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11146,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,73,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-11147,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11148,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,85,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11149,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,41,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11150,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11151,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,61,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11152,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,68,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11153,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,74,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11154,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,49,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11155,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,60,Female,White,North America,TNBC,Stage I,Control,Non-Responder
P-11156,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11157,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,59,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11158,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11159,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11160,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,43,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11161,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11162,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,50,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-11163,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Responder
P-11164,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,Asian,North America,TNBC,Stage I,Control,Non-Responder
P-11165,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,74,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11166,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,70,Male,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-11167,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,58,Female,White,North America,HR+/HER2+,Stage II,Control,Responder
P-11168,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,65,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11169,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,64,Female,Black/African American,North America,TNBC,Stage II,Experimental,Responder
P-11170,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,70,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11171,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,30,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11172,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,68,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11173,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,60,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11174,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,81,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11175,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,69,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11176,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,51,Female,White,Latin America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-11177,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,33,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-11178,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,74,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-11179,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11180,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,48,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11181,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11182,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,49,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11183,NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,Sanofi,54,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11184,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11185,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),60,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11186,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),36,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11187,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),48,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11188,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),61,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11189,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-11190,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),55,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11191,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),33,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11192,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11193,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),74,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11194,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),50,Female,Hispanic/Latino,North America,TNBC,Stage I,Experimental,Responder
P-11195,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11196,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,Other,North America,TNBC,Stage III,Experimental,Non-Responder
P-11197,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11198,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),79,Female,White,Asia-Pacific,HR+/HER2+,Stage II,Control,Non-Responder
P-11199,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11200,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11201,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-11202,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11203,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),81,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11204,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),50,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11205,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11206,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),63,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11207,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11208,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),45,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11209,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),73,Female,White,Latin America,HER2+,Stage II,Experimental,Responder
P-11210,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11211,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),31,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11212,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),77,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11213,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11214,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-11215,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),69,Female,White,Europe,TNBC,Stage III,Control,Responder
P-11216,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),54,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11217,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),61,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11218,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11219,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11220,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),52,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11221,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11222,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11223,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11224,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11225,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11226,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,Asia-Pacific,TNBC,Stage III,Control,Responder
P-11227,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11228,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),70,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11229,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),55,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11230,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,Black/African American,North America,TNBC,Stage I,Experimental,Responder
P-11231,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11232,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-11233,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11234,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),50,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-11235,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),75,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11236,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11237,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),63,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11238,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11239,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11240,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11241,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),61,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11242,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-11243,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-11244,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),77,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11245,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),36,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11246,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),69,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11247,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-11248,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11249,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),38,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11250,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11251,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11252,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,Hispanic/Latino,North America,HER2+,Stage II,Control,Non-Responder
P-11253,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11254,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-11255,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-11256,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),67,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11257,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),38,Female,Asian,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11258,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11259,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),70,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11260,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-11261,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11262,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11263,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,Asian,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-11264,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),36,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11265,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),32,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11266,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),60,Female,Other,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-11267,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),77,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11268,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11269,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11270,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11271,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),40,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Non-Responder
P-11272,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),60,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-11273,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),47,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-11274,NCT00369655,VEGF Trap in Treating Patients With Metastatic Breast Cancer,National Cancer Institute (NCI),72,Female,Asian,Europe,HER2+,Stage III,Control,Non-Responder
P-11275,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,51,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-11276,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,68,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-11277,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,52,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11278,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11279,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,61,Female,Hispanic/Latino,North America,TNBC,Stage II,Control,Non-Responder
P-11280,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11281,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11282,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,58,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11283,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,62,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Control,Responder
P-11284,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,72,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-11285,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,57,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11286,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,Asian,Europe,TNBC,Stage II,Experimental,Responder
P-11287,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,69,Female,Black/African American,Europe,HR+/HER2+,Stage III,Control,Non-Responder
P-11288,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,34,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11289,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11290,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,66,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Responder
P-11291,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,37,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11292,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,57,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11293,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,49,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-11294,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,78,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11295,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,62,Female,Hispanic/Latino,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-11296,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,51,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11297,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,52,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11298,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,59,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11299,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,55,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11300,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,64,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11301,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,68,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11302,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,73,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11303,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,79,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11304,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11305,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,66,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-11306,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,79,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Responder
P-11307,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,51,Female,White,Europe,TNBC,Stage II,Control,Responder
P-11308,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,88,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11309,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,53,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11310,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,78,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11311,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,63,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11312,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,69,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11313,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,32,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11314,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,37,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-11315,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,55,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11316,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,76,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11317,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,48,Female,Black/African American,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-11318,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,72,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11319,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,40,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11320,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,43,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11321,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,61,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11322,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,67,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11323,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,75,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-11324,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-11325,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,72,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11326,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,32,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11327,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,47,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11328,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,49,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11329,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,73,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11330,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,58,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11331,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,44,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11332,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,59,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11333,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,76,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11334,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11335,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-11336,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,56,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11337,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11338,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,56,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-11339,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,51,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11340,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,73,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-11341,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11342,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,44,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11343,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11344,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,75,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-11345,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,73,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11346,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11347,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,75,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11348,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,53,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11349,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,64,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11350,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,45,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11351,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,57,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11352,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11353,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,45,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11354,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,58,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11355,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11356,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,50,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Experimental,Non-Responder
P-11357,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,49,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11358,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11359,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,49,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-11360,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,59,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11361,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,52,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11362,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,42,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11363,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,81,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-11364,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,40,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11365,NCT04750889,Breast Localization: RFID Tags vs Wire Localization,Centre Jean Perrin,65,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11366,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,53,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11367,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,56,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11368,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,60,Female,Hispanic/Latino,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11369,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,46,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11370,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,34,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11371,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11372,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,Latin America,HR+/HER2-,Stage III,Control,Responder
P-11373,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,53,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11374,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,67,Female,White,North America,TNBC,Stage III,Control,Responder
P-11375,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-11376,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,Other,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11377,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,59,Female,White,Asia-Pacific,TNBC,Stage I,Control,Responder
P-11378,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11379,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,65,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11380,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,32,Female,White,Europe,TNBC,Stage I,Control,Responder
P-11381,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,48,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11382,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,47,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11383,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11384,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,50,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11385,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11386,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,47,Female,Other,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11387,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,46,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-11388,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,60,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11389,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11390,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11391,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11392,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,52,Female,Asian,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11393,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,84,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11394,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11395,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11396,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,73,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-11397,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11398,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,74,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11399,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11400,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11401,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,51,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11402,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,49,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Responder
P-11403,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,90,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11404,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,44,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-11405,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11406,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,83,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11407,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11408,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,42,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-11409,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11410,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,68,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11411,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11412,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,72,Female,Black/African American,North America,TNBC,Stage I,Experimental,Non-Responder
P-11413,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,85,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11414,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,57,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-11415,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,54,Female,Asian,Asia-Pacific,HR+/HER2+,Stage I,Experimental,Responder
P-11416,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,62,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11417,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,63,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11418,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,53,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11419,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11420,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11421,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11422,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,69,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-11423,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,50,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-11424,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,61,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-11425,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,61,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11426,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,39,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11427,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11428,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,33,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11429,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,59,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11430,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,65,Female,Asian,Europe,TNBC,Stage III,Control,Non-Responder
P-11431,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11432,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,72,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11433,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,67,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-11434,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11435,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,60,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11436,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,52,Female,White,Asia-Pacific,TNBC,Stage III,Control,Responder
P-11437,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,67,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11438,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,65,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11439,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11440,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,68,Female,Asian,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11441,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,74,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11442,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,36,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11443,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,31,Female,Black/African American,North America,TNBC,Stage II,Experimental,Non-Responder
P-11444,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,60,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-11445,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,76,Female,Asian,North America,TNBC,Stage II,Control,Non-Responder
P-11446,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,59,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11447,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,53,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11448,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,64,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11449,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11450,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,51,Female,White,Latin America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11451,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11452,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,71,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11453,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11454,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,46,Female,Black/African American,Europe,TNBC,Stage III,Control,Responder
P-11455,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11456,NCT03822468,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",Novartis Pharmaceuticals,73,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11457,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,43,Female,Black/African American,North America,TNBC,Stage III,Control,Responder
P-11458,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11459,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,61,Female,White,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-11460,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,45,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11461,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,66,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11462,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,57,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11463,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,49,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11464,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,44,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11465,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,67,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11466,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11467,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,57,Female,Asian,North America,HER2+,Stage III,Control,Responder
P-11468,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,50,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11469,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11470,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,56,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11471,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,78,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11472,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11473,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,69,Female,Asian,Asia-Pacific,HR+/HER2+,Stage III,Control,Non-Responder
P-11474,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11475,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,61,Female,Hispanic/Latino,North America,HER2+,Stage III,Experimental,Non-Responder
P-11476,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,62,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11477,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11478,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,46,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11479,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,78,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11480,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,47,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11481,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,69,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11482,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,70,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11483,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,58,Female,White,Europe,HR+/HER2+,Stage II,Control,Responder
P-11484,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,51,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11485,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,52,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11486,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,48,Female,Hispanic/Latino,North America,HER2+,Stage I,Control,Non-Responder
P-11487,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,43,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11488,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,52,Female,Black/African American,North America,TNBC,Stage I,Experimental,Non-Responder
P-11489,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,63,Female,Black/African American,North America,TNBC,Stage I,Experimental,Non-Responder
P-11490,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,44,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11491,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,62,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11492,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,42,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11493,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,71,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11494,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11495,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,50,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11496,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,55,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Responder
P-11497,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,48,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11498,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,64,Male,Black/African American,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11499,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,61,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11500,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,71,Female,White,Asia-Pacific,TNBC,Stage I,Experimental,Non-Responder
P-11501,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,67,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11502,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,66,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11503,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,53,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11504,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,75,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11505,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11506,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,33,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11507,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,47,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11508,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,47,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11509,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,78,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11510,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,44,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11511,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,38,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11512,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,48,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11513,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11514,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-11515,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11516,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,74,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11517,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11518,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,73,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-11519,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,77,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-11520,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,45,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11521,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,51,Female,White,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-11522,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,53,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11523,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,51,Female,Hispanic/Latino,Europe,TNBC,Stage III,Control,Non-Responder
P-11524,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,32,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11525,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11526,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11527,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,53,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-11528,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,48,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11529,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,71,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11530,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,59,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Responder
P-11531,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,62,Female,White,Europe,HER2+,Stage II,Control,Responder
P-11532,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,40,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-11533,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,72,Female,Hispanic/Latino,Latin America,TNBC,Stage II,Experimental,Responder
P-11534,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,83,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11535,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11536,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,62,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11537,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,30,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11538,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,50,Female,Asian,Europe,TNBC,Stage II,Experimental,Non-Responder
P-11539,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,69,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11540,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,52,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11541,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,61,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-11542,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,35,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11543,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11544,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11545,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11546,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,46,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11547,NCT00258050,To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients,GlaxoSmithKline,52,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11548,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,67,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11549,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,49,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11550,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,51,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11551,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,71,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11552,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,58,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-11553,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,53,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11554,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,53,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11555,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,46,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-11556,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,48,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11557,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11558,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,39,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-11559,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11560,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,64,Female,White,Europe,TNBC,Stage II,Control,Responder
P-11561,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,34,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11562,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,Asian,Europe,HR+/HER2+,Stage III,Control,Responder
P-11563,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,77,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11564,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,75,Female,Asian,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11565,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Non-Responder
P-11566,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,64,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11567,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,46,Female,Asian,North America,TNBC,Stage III,Control,Non-Responder
P-11568,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,39,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11569,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,48,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11570,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,57,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-11571,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,77,Female,Other,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11572,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,50,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11573,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11574,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,70,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11575,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,76,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-11576,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,37,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11577,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,74,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11578,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,51,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-11579,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11580,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,52,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11581,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,64,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-11582,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,69,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11583,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,56,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11584,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11585,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,54,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11586,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,65,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11587,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11588,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,51,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-11589,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11590,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,70,Female,Black/African American,North America,HER2+,Stage III,Experimental,Responder
P-11591,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,84,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11592,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,56,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11593,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,62,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11594,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,64,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-11595,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,56,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-11596,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11597,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,58,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11598,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,59,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-11599,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11600,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,48,Female,Hispanic/Latino,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-11601,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,36,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-11602,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,44,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11603,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,55,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-11604,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11605,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,72,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11606,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,59,Female,Asian,Europe,HER2+,Stage II,Experimental,Non-Responder
P-11607,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,51,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11608,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,44,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11609,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11610,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,43,Female,Black/African American,North America,HER2+,Stage III,Experimental,Responder
P-11611,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,35,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11612,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,54,Female,White,Latin America,HER2+,Stage II,Control,Responder
P-11613,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,46,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11614,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,60,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11615,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,57,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-11616,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,54,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11617,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-11618,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,36,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-11619,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,75,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11620,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,72,Female,Other,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11621,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,38,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11622,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,28,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11623,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,55,Female,White,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-11624,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,48,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-11625,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,62,Female,Asian,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-11626,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,66,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11627,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,68,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11628,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11629,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,56,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11630,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,48,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-11631,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,50,Female,Asian,Europe,HER2+,Stage II,Experimental,Responder
P-11632,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,65,Female,Asian,North America,HER2+,Stage III,Control,Responder
P-11633,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11634,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,55,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11635,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11636,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,47,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-11637,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,56,Male,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11638,NCT01115374,Lymphedema Therapy With Sound Wave Lymphatic Drainage,Fundacion IMIM,60,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11639,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,45,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Experimental,Non-Responder
P-11640,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,47,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11641,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,65,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11642,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,58,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11643,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,40,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11644,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,48,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-11645,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11646,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,67,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11647,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,38,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11648,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,62,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11649,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,28,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11650,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11651,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,48,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11652,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,73,Female,White,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-11653,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,48,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11654,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,76,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11655,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11656,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,53,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11657,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,45,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11658,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,59,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-11659,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,56,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11660,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11661,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Responder
P-11662,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,57,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11663,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,67,Female,Asian,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-11664,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11665,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11666,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11667,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,52,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11668,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,64,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-11669,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,48,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11670,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,43,Female,Hispanic/Latino,Europe,HR+/HER2+,Stage III,Control,Responder
P-11671,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11672,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11673,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,64,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11674,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,51,Female,White,Europe,HR+/HER2+,Stage II,Control,Responder
P-11675,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,59,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11676,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11677,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,70,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-11678,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,64,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-11679,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,40,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11680,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,80,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11681,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,50,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11682,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,51,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-11683,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,75,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11684,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,36,Female,White,North America,HER2+,Stage III,Control,Responder
P-11685,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,49,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11686,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,46,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11687,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,84,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11688,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,70,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-11689,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,57,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11690,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11691,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,55,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-11692,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,56,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11693,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,58,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11694,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,57,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11695,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,54,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11696,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,68,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11697,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,61,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11698,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,72,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11699,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11700,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,53,Female,Asian,North America,TNBC,Stage III,Experimental,Non-Responder
P-11701,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,34,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11702,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,63,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-11703,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,76,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11704,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,83,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11705,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,62,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11706,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,39,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-11707,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,59,Female,White,Europe,HER2+,Stage II,Control,Responder
P-11708,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,65,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11709,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11710,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,53,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11711,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,57,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11712,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,59,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-11713,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,63,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-11714,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,59,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11715,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,60,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11716,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,69,Female,Hispanic/Latino,Latin America,HER2+,Stage I,Experimental,Non-Responder
P-11717,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,68,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11718,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,67,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-11719,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,68,Female,White,Europe,TNBC,Stage I,Experimental,Non-Responder
P-11720,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,38,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-11721,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,53,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11722,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11723,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,54,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11724,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,64,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11725,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,38,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11726,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,81,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11727,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,42,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11728,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11729,NCT04829643,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,IRCCS San Raffaele,50,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11730,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,69,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11731,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,52,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11732,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,47,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11733,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11734,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,66,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-11735,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,67,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11736,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,55,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11737,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11738,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,33,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-11739,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,50,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11740,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,52,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-11741,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,67,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11742,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,68,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11743,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,69,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-11744,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,54,Female,White,Latin America,TNBC,Stage III,Experimental,Non-Responder
P-11745,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,71,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11746,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,59,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-11747,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11748,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11749,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,42,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11750,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,71,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Control,Responder
P-11751,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,67,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-11752,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,55,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11753,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,66,Female,Asian,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-11754,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,72,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-11755,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,48,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11756,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,74,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11757,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,46,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11758,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,73,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11759,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11760,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,65,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11761,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,63,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11762,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11763,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,65,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-11764,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,58,Female,White,Europe,HER2+,Stage III,Control,Responder
P-11765,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,32,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11766,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,55,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11767,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,83,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11768,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,45,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11769,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,57,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11770,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,45,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11771,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,35,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11772,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,82,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11773,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11774,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11775,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,45,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11776,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,58,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11777,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,54,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-11778,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,52,Female,White,Europe,HER2+,Stage II,Control,Responder
P-11779,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,58,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-11780,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,64,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11781,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,65,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-11782,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,51,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11783,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11784,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,25,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11785,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,84,Female,White,North America,HER2+,Stage II,Control,Responder
P-11786,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,62,Female,Hispanic/Latino,North America,HER2+,Stage II,Experimental,Responder
P-11787,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,55,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11788,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,62,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11789,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,90,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11790,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,64,Female,White,Latin America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-11791,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,70,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11792,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,52,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11793,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,72,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11794,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11795,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,47,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11796,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,57,Female,Black/African American,North America,TNBC,Stage III,Control,Responder
P-11797,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11798,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,77,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11799,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,63,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11800,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,65,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11801,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11802,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11803,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,47,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11804,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11805,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,68,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11806,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,49,Female,Hispanic/Latino,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-11807,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,78,Female,Other,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11808,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,29,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11809,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,69,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11810,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,69,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11811,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,56,Female,White,Europe,TNBC,Stage III,Control,Responder
P-11812,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,68,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11813,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11814,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,79,Female,Asian,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-11815,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,73,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-11816,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,56,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11817,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,76,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11818,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,57,Female,White,Asia-Pacific,HER2+,Stage I,Control,Non-Responder
P-11819,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,41,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11820,NCT01271725,LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures,Boehringer Ingelheim,54,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11821,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),46,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11822,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),60,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11823,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),61,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11824,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),63,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-11825,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),67,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11826,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),66,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-11827,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),38,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11828,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),73,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11829,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11830,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),59,Female,Black/African American,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-11831,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),41,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11832,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),40,Female,White,Europe,HER2+,Stage I,Experimental,Non-Responder
P-11833,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11834,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),38,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11835,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),51,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11836,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),65,Female,Asian,North America,TNBC,Stage II,Experimental,Responder
P-11837,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-11838,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),64,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11839,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),59,Female,Black/African American,North America,TNBC,Stage III,Control,Responder
P-11840,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11841,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),50,Female,Other,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11842,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11843,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),45,Female,Asian,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11844,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),50,Female,White,North America,TNBC,Stage I,Experimental,Non-Responder
P-11845,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),70,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11846,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),49,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-11847,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),34,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-11848,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),60,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11849,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),34,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11850,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),56,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11851,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11852,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),79,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11853,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),69,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11854,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),71,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage III,Experimental,Responder
P-11855,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11856,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),68,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-11857,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),48,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11858,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),61,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11859,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11860,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11861,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),63,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11862,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),60,Female,Asian,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11863,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),73,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-11864,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11865,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11866,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-11867,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),46,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11868,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),37,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11869,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11870,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11871,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),51,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11872,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),53,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11873,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),77,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11874,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),57,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-11875,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),37,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-11876,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),37,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-11877,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),54,Female,White,Latin America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-11878,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),56,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11879,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),77,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-11880,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),72,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-11881,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),46,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11882,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),52,Female,White,North America,HER2+,Stage III,Control,Responder
P-11883,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),31,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11884,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),65,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11885,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),53,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11886,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),34,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11887,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),49,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11888,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),75,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-11889,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11890,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),41,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-11891,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),75,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-11892,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),75,Female,White,Asia-Pacific,TNBC,Stage I,Control,Responder
P-11893,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),61,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-11894,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),60,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-11895,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11896,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11897,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),47,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11898,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),49,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-11899,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),53,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11900,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),62,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11901,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),75,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-11902,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),78,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11903,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11904,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),31,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-11905,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),48,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-11906,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),63,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-11907,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),58,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11908,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),36,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11909,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),36,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11910,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),53,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11911,NCT00077376,"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer",National Cancer Institute (NCI),79,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11912,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,70,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11913,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,55,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11914,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,81,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11915,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,48,Female,White,North America,HR+/HER2+,Stage II,Control,Responder
P-11916,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11917,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,42,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-11918,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,65,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11919,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,48,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11920,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,87,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11921,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,40,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-11922,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,65,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-11923,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,47,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-11924,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,40,Female,Asian,North America,HR+/HER2+,Stage III,Control,Responder
P-11925,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,79,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-11926,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,37,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-11927,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,53,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-11928,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,30,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-11929,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-11930,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,66,Female,White,North America,TNBC,Stage II,Control,Responder
P-11931,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,66,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11932,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,66,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11933,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,68,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11934,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,45,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11935,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,42,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Non-Responder
P-11936,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,54,Female,Black/African American,Europe,TNBC,Stage I,Control,Non-Responder
P-11937,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,74,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11938,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11939,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,70,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-11940,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,50,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11941,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11942,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,80,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11943,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11944,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-11945,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-11946,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,73,Female,White,North America,TNBC,Stage II,Control,Responder
P-11947,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,65,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-11948,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11949,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,50,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-11950,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,49,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-11951,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,61,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11952,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,50,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11953,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,71,Female,White,Latin America,TNBC,Stage II,Experimental,Responder
P-11954,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,40,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-11955,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,34,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-11956,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11957,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-11958,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,47,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-11959,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,71,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11960,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,63,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11961,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,51,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-11962,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11963,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,39,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-11964,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,50,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11965,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,46,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11966,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,62,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11967,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,65,Female,Hispanic/Latino,North America,HER2+,Stage II,Experimental,Responder
P-11968,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,59,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11969,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,47,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-11970,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,50,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-11971,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,70,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11972,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,72,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11973,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11974,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,58,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-11975,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,46,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11976,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,64,Female,Hispanic/Latino,North America,HER2+,Stage III,Experimental,Non-Responder
P-11977,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,57,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11978,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,73,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-11979,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,55,Female,Black/African American,North America,TNBC,Stage II,Control,Responder
P-11980,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,40,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11981,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,70,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11982,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,46,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-11983,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,53,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11984,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11985,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,49,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-11986,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,42,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-11987,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,34,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-11988,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-11989,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,44,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11990,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,48,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11991,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-11992,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,39,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-11993,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,62,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-11994,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,78,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-11995,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,74,Female,White,North America,HER2+,Stage II,Control,Responder
P-11996,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,66,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-11997,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,55,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-11998,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,75,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-11999,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,52,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-12000,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,60,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12001,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,56,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12002,NCT04980989,Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software,Helsinki University Central Hospital,34,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12003,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12004,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,43,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12005,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,69,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12006,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,75,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-12007,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,53,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12008,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,68,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12009,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,57,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12010,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,45,Female,Hispanic/Latino,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12011,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-12012,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,45,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12013,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12014,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,66,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12015,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,68,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12016,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12017,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12018,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,Asian,North America,TNBC,Stage II,Experimental,Non-Responder
P-12019,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,33,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12020,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12021,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12022,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,90,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-12023,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-12024,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,51,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12025,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,55,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12026,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,78,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12027,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,70,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12028,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,51,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12029,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,73,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-12030,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,70,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12031,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,67,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-12032,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,62,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12033,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,56,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-12034,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12035,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,56,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12036,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,25,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12037,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,78,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12038,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12039,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,53,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Responder
P-12040,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,36,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12041,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,67,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-12042,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,45,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-12043,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,70,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12044,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,66,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12045,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,48,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12046,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,59,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-12047,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12048,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,77,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12049,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12050,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,47,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12051,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,38,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12052,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,62,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12053,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,57,Female,White,Europe,HER2+,Stage III,Control,Responder
P-12054,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,49,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12055,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,52,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12056,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,62,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12057,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,68,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12058,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12059,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,48,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12060,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,62,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12061,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,55,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-12062,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,32,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12063,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,49,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12064,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12065,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,32,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-12066,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,70,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12067,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,76,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-12068,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,68,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12069,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,80,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12070,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,60,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-12071,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,65,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-12072,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,57,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12073,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,55,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12074,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12075,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,52,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12076,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,64,Female,Other,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Responder
P-12077,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,73,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12078,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12079,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,83,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12080,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,41,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12081,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,64,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12082,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,41,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12083,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12084,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,56,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-12085,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,69,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12086,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,58,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12087,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,57,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12088,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,43,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12089,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12090,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,54,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12091,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,49,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-12092,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,83,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12093,NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,Chinese Academy of Medical Sciences,52,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12094,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,89,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12095,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,38,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12096,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,78,Female,Black/African American,Europe,HER2+,Stage III,Control,Non-Responder
P-12097,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,62,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12098,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12099,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,79,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12100,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,54,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-12101,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12102,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,66,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12103,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,41,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12104,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,31,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12105,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12106,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12107,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,58,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12108,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,42,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12109,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12110,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,56,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12111,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,58,Male,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12112,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12113,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,51,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12114,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-12115,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12116,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,63,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12117,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,68,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12118,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,33,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-12119,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,63,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12120,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,60,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12121,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12122,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,79,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12123,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-12124,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,85,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12125,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,74,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12126,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,55,Female,Black/African American,Europe,TNBC,Stage II,Control,Responder
P-12127,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12128,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,63,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12129,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,68,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12130,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,63,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-12131,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12132,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,49,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-12133,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,58,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12134,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,48,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12135,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,61,Female,Other,North America,TNBC,Stage III,Experimental,Responder
P-12136,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,77,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12137,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,65,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12138,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-12139,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12140,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,74,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-12141,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,69,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12142,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12143,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12144,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,62,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12145,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,40,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-12146,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,52,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-12147,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12148,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-12149,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,52,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12150,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,72,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12151,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,63,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12152,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,25,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Non-Responder
P-12153,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,62,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12154,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,54,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-12155,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12156,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,74,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12157,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,69,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12158,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,44,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12159,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,72,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12160,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,Hispanic/Latino,Europe,TNBC,Stage II,Experimental,Non-Responder
P-12161,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,62,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12162,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,34,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12163,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12164,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,34,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12165,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,64,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12166,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,79,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12167,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12168,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12169,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,25,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12170,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,59,Female,White,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-12171,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,69,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12172,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,72,Female,Black/African American,North America,HER2+,Stage III,Control,Non-Responder
P-12173,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,67,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12174,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12175,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12176,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,43,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12177,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,57,Female,White,Asia-Pacific,HER2+,Stage I,Control,Non-Responder
P-12178,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12179,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,50,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12180,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,53,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12181,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,61,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12182,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,71,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12183,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,48,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12184,NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,UNC Lineberger Comprehensive Cancer Center,59,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12185,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,77,Female,White,North America,HER2+,Stage III,Control,Responder
P-12186,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12187,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12188,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,48,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12189,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,41,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12190,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12191,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,53,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12192,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,67,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-12193,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12194,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,55,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12195,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,84,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12196,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,54,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12197,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,59,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12198,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,Other,North America,HER2+,Stage I,Control,Non-Responder
P-12199,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,58,Female,Asian,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-12200,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,48,Female,White,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-12201,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12202,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,53,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12203,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,57,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12204,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,42,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12205,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12206,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,57,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-12207,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,43,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12208,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12209,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,64,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-12210,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,46,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-12211,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,62,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12212,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,81,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-12213,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,80,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12214,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12215,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,62,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12216,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Non-Responder
P-12217,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,65,Male,Black/African American,North America,HER2+,Stage I,Experimental,Non-Responder
P-12218,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,61,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12219,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,41,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12220,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,76,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12221,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,58,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12222,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,47,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-12223,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12224,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,65,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12225,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,41,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12226,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12227,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12228,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,70,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12229,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,66,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-12230,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,82,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12231,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,75,Female,White,Europe,HER2+,Stage III,Control,Responder
P-12232,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,59,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12233,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,30,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12234,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,78,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12235,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,45,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12236,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12237,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,Other,Europe,HER2+,Stage II,Control,Non-Responder
P-12238,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12239,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,54,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12240,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12241,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,82,Female,Asian,Europe,TNBC,Stage I,Control,Non-Responder
P-12242,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,42,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-12243,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,65,Male,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12244,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,58,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12245,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,70,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12246,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,White,Asia-Pacific,HR+/HER2+,Stage II,Control,Non-Responder
P-12247,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12248,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,60,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-12249,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,47,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12250,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,53,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12251,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,56,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12252,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,57,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12253,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,63,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-12254,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,52,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12255,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,45,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12256,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,54,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12257,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,44,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-12258,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,70,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-12259,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,34,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12260,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,56,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-12261,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,84,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12262,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,45,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-12263,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,71,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12264,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12265,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,65,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-12266,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,45,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12267,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,49,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12268,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,30,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12269,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12270,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,50,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12271,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,80,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12272,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,59,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12273,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,47,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12274,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,44,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12275,NCT01440855,Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting,Fox Chase Cancer Center,59,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-12276,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",50,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12277,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",45,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12278,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12279,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",47,Female,Hispanic/Latino,Europe,HER2+,Stage III,Experimental,Non-Responder
P-12280,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",60,Male,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12281,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12282,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",50,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12283,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",68,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12284,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,White,Asia-Pacific,TNBC,Stage III,Control,Responder
P-12285,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-12286,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",79,Female,Other,North America,HER2+,Stage II,Control,Non-Responder
P-12287,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",60,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12288,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12289,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12290,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",60,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12291,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",55,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12292,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",66,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12293,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-12294,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",64,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12295,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12296,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",40,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12297,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",34,Female,Black/African American,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-12298,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",51,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12299,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",49,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12300,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12301,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12302,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12303,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",58,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12304,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",47,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12305,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",65,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Control,Non-Responder
P-12306,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",64,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-12307,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12308,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",51,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12309,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",46,Female,Black/African American,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12310,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12311,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12312,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",69,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-12313,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",50,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Control,Responder
P-12314,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",44,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-12315,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12316,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",47,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12317,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12318,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",73,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12319,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",48,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12320,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",51,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12321,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",57,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12322,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",57,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12323,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12324,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12325,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",53,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12326,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",46,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12327,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",52,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12328,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",45,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-12329,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",61,Male,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-12330,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12331,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",59,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12332,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",59,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12333,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",55,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12334,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",68,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-12335,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",73,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12336,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",74,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12337,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",32,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12338,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",46,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-12339,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",47,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-12340,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",54,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-12341,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",45,Female,Hispanic/Latino,North America,TNBC,Stage III,Experimental,Non-Responder
P-12342,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",68,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12343,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12344,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",54,Female,Asian,North America,TNBC,Stage II,Experimental,Non-Responder
P-12345,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",53,Female,Asian,Asia-Pacific,HR+/HER2+,Stage II,Experimental,Responder
P-12346,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",55,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-12347,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",57,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12348,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",61,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12349,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",26,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12350,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12351,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",56,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12352,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",71,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12353,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",85,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12354,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",38,Female,Black/African American,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-12355,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",75,Female,Black/African American,Europe,HER2+,Stage III,Experimental,Non-Responder
P-12356,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",70,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12357,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",64,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12358,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,Black/African American,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12359,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",63,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12360,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",49,Female,Other,Europe,HR+/HER2+,Stage III,Experimental,Non-Responder
P-12361,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",54,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-12362,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",73,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12363,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12364,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12365,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12366,NCT03313908,Radioguided Occult Lesion Localisation by Indocyanine Green,"University Hospital, Montpellier",62,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12367,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,53,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12368,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,47,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-12369,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,56,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-12370,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,44,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12371,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,64,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12372,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,82,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12373,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,42,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12374,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,43,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-12375,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12376,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,55,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12377,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,77,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12378,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,58,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-12379,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,59,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12380,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,64,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12381,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,75,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-12382,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-12383,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,74,Female,Other,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-12384,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,60,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-12385,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,59,Female,Asian,North America,HER2+,Stage II,Control,Responder
P-12386,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,77,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12387,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,47,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12388,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,68,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12389,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,61,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12390,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,66,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-12391,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,64,Female,White,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-12392,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,80,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12393,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,63,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12394,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12395,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12396,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,54,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12397,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,42,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12398,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,53,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12399,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12400,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,37,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12401,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,61,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12402,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Control,Responder
P-12403,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,57,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-12404,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,69,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-12405,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,71,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12406,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,61,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12407,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,39,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-12408,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,67,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12409,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,53,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12410,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,51,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12411,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12412,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,81,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12413,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,44,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12414,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,81,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12415,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,59,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12416,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,52,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12417,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,70,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12418,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12419,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,68,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12420,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,71,Male,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12421,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,72,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-12422,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,47,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-12423,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-12424,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,50,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12425,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,59,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-12426,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12427,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,46,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12428,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,74,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12429,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,65,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-12430,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,54,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12431,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,56,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12432,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,49,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12433,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,53,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-12434,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,44,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12435,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,51,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12436,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,90,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12437,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,53,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12438,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12439,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,81,Female,Other,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-12440,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,66,Female,White,North America,TNBC,Stage I,Experimental,Non-Responder
P-12441,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,35,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-12442,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,59,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12443,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,77,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-12444,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,42,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12445,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,63,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12446,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12447,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,57,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12448,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,62,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12449,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,72,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12450,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,76,Female,Asian,Latin America,HR+/HER2+,Stage II,Control,Responder
P-12451,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,47,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12452,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,61,Male,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-12453,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,44,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12454,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,41,Female,Asian,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12455,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,48,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12456,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,38,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12457,NCT05364450,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,Indiana University,54,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12458,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,63,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12459,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,43,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-12460,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,37,Female,Hispanic/Latino,North America,HER2+,Stage II,Experimental,Responder
P-12461,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,55,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12462,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,71,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12463,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,54,Female,Asian,North America,HR+/HER2-,Stage I,Control,Responder
P-12464,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,82,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12465,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,72,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12466,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,61,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12467,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,31,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12468,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12469,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,68,Female,White,North America,HER2+,Stage II,Control,Responder
P-12470,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,81,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12471,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,57,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12472,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12473,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12474,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,37,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12475,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,31,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12476,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,25,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12477,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12478,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,47,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12479,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,45,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-12480,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,43,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-12481,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,39,Female,Asian,Europe,HER2+,Stage II,Experimental,Responder
P-12482,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,62,Female,Black/African American,Latin America,HR+/HER2+,Stage II,Experimental,Responder
P-12483,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,54,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12484,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,65,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12485,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,66,Female,Black/African American,North America,TNBC,Stage III,Experimental,Non-Responder
P-12486,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,65,Female,Hispanic/Latino,North America,TNBC,Stage II,Experimental,Responder
P-12487,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,47,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12488,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,45,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12489,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,52,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12490,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,49,Female,Black/African American,North America,HER2+,Stage I,Control,Non-Responder
P-12491,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,69,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-12492,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,69,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-12493,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,40,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12494,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,69,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12495,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,66,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12496,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,71,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12497,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,60,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12498,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12499,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12500,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12501,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12502,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,44,Female,White,North America,TNBC,Stage I,Control,Responder
P-12503,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,46,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-12504,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,53,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12505,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,31,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12506,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,47,Male,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12507,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,North America,TNBC,Stage III,Control,Responder
P-12508,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12509,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,46,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12510,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,61,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12511,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,66,Female,Black/African American,Latin America,HER2+,Stage III,Experimental,Responder
P-12512,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,56,Female,Black/African American,Asia-Pacific,HR+/HER2+,Stage II,Control,Non-Responder
P-12513,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,50,Female,Asian,North America,TNBC,Stage III,Experimental,Responder
P-12514,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,27,Female,White,Europe,HER2+,Stage III,Control,Responder
P-12515,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12516,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,57,Female,White,Latin America,HER2+,Stage II,Experimental,Responder
P-12517,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,Asian,North America,TNBC,Stage III,Experimental,Responder
P-12518,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,64,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12519,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,64,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12520,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,72,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12521,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,73,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12522,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,26,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12523,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,29,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12524,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,60,Male,Hispanic/Latino,North America,HER2+,Stage III,Experimental,Non-Responder
P-12525,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,57,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12526,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,51,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12527,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,48,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12528,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,59,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12529,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,51,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12530,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,66,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12531,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,43,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12532,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,60,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12533,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12534,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,70,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12535,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,40,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12536,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12537,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,53,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12538,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12539,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,69,Female,Other,Latin America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12540,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12541,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,67,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12542,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,56,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12543,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,63,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12544,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,56,Female,Asian,North America,HER2+,Stage III,Experimental,Non-Responder
P-12545,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12546,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,70,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-12547,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,53,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Responder
P-12548,NCT06246084,INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy,Dana-Farber Cancer Institute,67,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12549,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,55,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12550,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-12551,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,48,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12552,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12553,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,35,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12554,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12555,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12556,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,66,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12557,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,68,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-12558,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12559,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,25,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12560,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,66,Female,Black/African American,North America,TNBC,Stage II,Control,Responder
P-12561,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12562,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,Black/African American,North America,HER2+,Stage II,Control,Non-Responder
P-12563,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,67,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12564,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12565,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,44,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12566,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,65,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-12567,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,90,Female,Asian,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12568,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-12569,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,63,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12570,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,76,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12571,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,White,Europe,HER2+,Stage II,Control,Responder
P-12572,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,79,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12573,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,81,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12574,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,63,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12575,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,46,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12576,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,43,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12577,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,34,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12578,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,59,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12579,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,66,Male,White,Latin America,TNBC,Stage II,Experimental,Responder
P-12580,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,51,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12581,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,48,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12582,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12583,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12584,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,51,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-12585,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,66,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12586,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,55,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12587,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,52,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-12588,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,50,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12589,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,68,Male,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-12590,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12591,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12592,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,72,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-12593,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12594,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,65,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12595,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,65,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12596,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12597,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,78,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12598,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,76,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12599,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,37,Female,Other,Latin America,TNBC,Stage II,Experimental,Non-Responder
P-12600,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,42,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-12601,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,68,Female,Hispanic/Latino,Europe,HER2+,Stage II,Experimental,Responder
P-12602,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,39,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12603,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,73,Female,White,Europe,HR+/HER2+,Stage III,Control,Non-Responder
P-12604,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,63,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12605,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12606,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,49,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12607,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12608,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12609,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,68,Female,White,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-12610,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,61,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12611,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,48,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12612,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,57,Female,Black/African American,Europe,TNBC,Stage III,Control,Non-Responder
P-12613,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,67,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-12614,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,45,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12615,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,50,Female,Other,North America,TNBC,Stage III,Control,Responder
P-12616,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,42,Female,White,Europe,HR+/HER2+,Stage I,Experimental,Responder
P-12617,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,46,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12618,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,48,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12619,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,62,Female,Asian,Europe,TNBC,Stage III,Experimental,Responder
P-12620,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,69,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12621,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,47,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-12622,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,64,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12623,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,78,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12624,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,46,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-12625,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,61,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12626,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,51,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12627,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,51,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12628,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,67,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12629,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,49,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12630,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,53,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12631,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-12632,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,54,Female,White,Asia-Pacific,HR+/HER2+,Stage II,Experimental,Non-Responder
P-12633,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12634,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12635,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,38,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-12636,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,61,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-12637,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,77,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12638,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,62,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12639,NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,University of Washington,51,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12640,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,83,Female,Black/African American,North America,HER2+,Stage III,Control,Responder
P-12641,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,50,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12642,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,68,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12643,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12644,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12645,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,74,Male,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12646,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,67,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12647,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,46,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12648,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,72,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12649,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,70,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12650,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12651,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,39,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12652,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,78,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12653,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,59,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12654,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,78,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12655,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,48,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12656,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,42,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-12657,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,68,Female,White,Latin America,HER2+,Stage III,Control,Non-Responder
P-12658,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,46,Female,White,Europe,TNBC,Stage II,Control,Responder
P-12659,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,55,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12660,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,57,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12661,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12662,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,56,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-12663,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,60,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12664,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12665,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,31,Male,Asian,North America,TNBC,Stage II,Experimental,Non-Responder
P-12666,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,61,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12667,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12668,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12669,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12670,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,62,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-12671,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,45,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12672,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,49,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-12673,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,65,Female,White,Europe,HER2+,Stage III,Control,Responder
P-12674,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,69,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Responder
P-12675,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,71,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12676,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12677,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12678,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,83,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-12679,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,62,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12680,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,50,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12681,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,52,Female,Hispanic/Latino,Europe,TNBC,Stage II,Experimental,Responder
P-12682,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12683,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,80,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-12684,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,76,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12685,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,46,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-12686,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,53,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12687,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,58,Female,Black/African American,North America,HER2+,Stage II,Control,Responder
P-12688,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,58,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-12689,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,62,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12690,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,75,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12691,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,88,Female,Other,North America,HER2+,Stage II,Experimental,Responder
P-12692,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,66,Female,Black/African American,North America,HER2+,Stage I,Control,Non-Responder
P-12693,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,63,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12694,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,38,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12695,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12696,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,61,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-12697,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,46,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12698,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,66,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12699,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,29,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12700,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,53,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-12701,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,71,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12702,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,41,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12703,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,52,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12704,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12705,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,60,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12706,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,76,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12707,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,58,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12708,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,47,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12709,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,59,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-12710,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,74,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12711,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,68,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12712,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,25,Female,Asian,Europe,TNBC,Stage III,Experimental,Responder
P-12713,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,60,Male,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12714,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,63,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-12715,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,64,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-12716,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,59,Female,White,Latin America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-12717,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,63,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12718,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,43,Female,Asian,Latin America,TNBC,Stage III,Control,Non-Responder
P-12719,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,75,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12720,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,55,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12721,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,62,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12722,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,63,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12723,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,52,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-12724,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,50,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12725,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,69,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12726,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,50,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-12727,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,71,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12728,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,60,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12729,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,66,Male,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12730,NCT03832985,Pediatric Reporting of Adult-Onset Genomic Results,Geisinger Clinic,63,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12731,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,46,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-12732,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12733,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12734,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,60,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12735,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,67,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12736,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,42,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12737,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,50,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12738,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12739,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12740,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,36,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-12741,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12742,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12743,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12744,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12745,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,53,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-12746,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,65,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-12747,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,38,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12748,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,73,Female,Other,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12749,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12750,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,58,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-12751,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,77,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12752,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,76,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12753,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12754,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,72,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-12755,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,66,Female,White,North America,TNBC,Stage II,Control,Responder
P-12756,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,38,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12757,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,68,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12758,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,53,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12759,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12760,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,48,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12761,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,65,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12762,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12763,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,44,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12764,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,59,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-12765,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,49,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12766,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,53,Female,Black/African American,Europe,HER2+,Stage II,Control,Responder
P-12767,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,65,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-12768,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,65,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12769,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,25,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12770,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,83,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12771,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,56,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12772,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12773,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,40,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-12774,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,57,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-12775,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,51,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-12776,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,54,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12777,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,54,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12778,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,30,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Control,Responder
P-12779,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,60,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-12780,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,62,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-12781,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12782,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,50,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-12783,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12784,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,61,Female,White,North America,HER2+,Stage II,Control,Responder
P-12785,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,72,Female,Other,Europe,HER2+,Stage III,Control,Non-Responder
P-12786,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,53,Female,White,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-12787,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12788,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,64,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12789,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,46,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12790,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,44,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12791,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12792,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,80,Male,Asian,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-12793,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,70,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-12794,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,75,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12795,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,68,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12796,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12797,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,White,North America,TNBC,Stage I,Control,Responder
P-12798,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,47,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-12799,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,45,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-12800,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,76,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12801,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,47,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-12802,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,42,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12803,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12804,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12805,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,47,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12806,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,35,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12807,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12808,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,65,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-12809,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,56,Female,White,Europe,TNBC,Stage III,Control,Responder
P-12810,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,57,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-12811,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,41,Female,Asian,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12812,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,51,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12813,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,28,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12814,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,39,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12815,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,73,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12816,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,59,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-12817,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,37,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-12818,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12819,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12820,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,43,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12821,NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Norwegian Institute of Public Health,66,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-12822,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,45,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12823,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,52,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12824,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,60,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12825,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,51,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12826,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,50,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12827,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,67,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12828,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12829,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12830,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,46,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-12831,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,57,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12832,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,49,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12833,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,63,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12834,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,51,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12835,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,61,Female,White,Europe,TNBC,Stage III,Control,Responder
P-12836,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,48,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12837,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,42,Female,Asian,North America,HER2+,Stage III,Experimental,Responder
P-12838,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,59,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-12839,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,55,Female,White,Asia-Pacific,HR+/HER2+,Stage I,Control,Non-Responder
P-12840,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,50,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12841,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,76,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12842,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,39,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12843,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,55,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12844,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12845,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,66,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12846,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,72,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-12847,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,64,Female,Black/African American,North America,TNBC,Stage II,Control,Responder
P-12848,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12849,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,31,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-12850,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-12851,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,60,Female,Other,North America,HER2+,Stage III,Experimental,Non-Responder
P-12852,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12853,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,79,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-12854,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,70,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-12855,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,Asian,North America,HER2+,Stage III,Control,Non-Responder
P-12856,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,63,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12857,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12858,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,49,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Non-Responder
P-12859,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,78,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12860,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,64,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-12861,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,78,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-12862,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,46,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12863,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,55,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12864,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,60,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12865,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,38,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12866,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-12867,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,67,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12868,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12869,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,69,Female,White,North America,TNBC,Stage II,Control,Responder
P-12870,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,47,Female,Other,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12871,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-12872,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,73,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12873,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,39,Female,Asian,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-12874,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-12875,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12876,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,37,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12877,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,54,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12878,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,42,Female,Asian,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-12879,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,59,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12880,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,50,Female,Asian,Europe,TNBC,Stage III,Experimental,Responder
P-12881,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,34,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12882,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,59,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-12883,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,65,Female,Black/African American,Europe,TNBC,Stage II,Control,Non-Responder
P-12884,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,55,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-12885,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-12886,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,78,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12887,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12888,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,76,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12889,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,Black/African American,Europe,HER2+,Stage III,Control,Non-Responder
P-12890,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,86,Male,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12891,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,48,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12892,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,39,Female,Black/African American,Asia-Pacific,HER2+,Stage I,Experimental,Responder
P-12893,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,67,Female,Black/African American,North America,HER2+,Stage II,Control,Non-Responder
P-12894,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,60,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-12895,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,33,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-12896,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,64,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-12897,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,51,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-12898,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12899,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,40,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-12900,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,61,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-12901,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,46,Female,Black/African American,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12902,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,62,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12903,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,50,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12904,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,36,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12905,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,54,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12906,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,58,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-12907,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,63,Female,Asian,North America,TNBC,Stage II,Control,Responder
P-12908,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,44,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-12909,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,60,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12910,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,66,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-12911,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,57,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-12912,NCT04224272,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Jazz Pharmaceuticals,56,Female,Black/African American,North America,TNBC,Stage II,Experimental,Responder
P-12913,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,54,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12914,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,69,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12915,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,53,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12916,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,46,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-12917,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,51,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12918,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,77,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12919,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,74,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12920,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,White,Europe,HER2+,Stage I,Control,Non-Responder
P-12921,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,Asian,Europe,TNBC,Stage II,Control,Non-Responder
P-12922,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12923,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,25,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12924,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12925,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,82,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12926,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,43,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-12927,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12928,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-12929,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,49,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-12930,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,50,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12931,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,69,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-12932,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12933,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,37,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12934,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,77,Female,Hispanic/Latino,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-12935,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,44,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-12936,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,85,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-12937,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-12938,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-12939,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,32,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-12940,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,44,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12941,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,31,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12942,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-12943,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,78,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-12944,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,57,Female,Asian,North America,TNBC,Stage II,Control,Non-Responder
P-12945,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,45,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-12946,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,63,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12947,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,58,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-12948,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12949,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,45,Female,White,North America,HR+/HER2+,Stage III,Control,Responder
P-12950,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12951,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,73,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-12952,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,39,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12953,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,56,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12954,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,65,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-12955,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,78,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12956,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,37,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-12957,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,75,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-12958,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,35,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-12959,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,38,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-12960,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,75,Female,White,North America,HR+/HER2+,Stage I,Experimental,Responder
P-12961,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12962,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,72,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Responder
P-12963,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,61,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-12964,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-12965,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,55,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-12966,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,71,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-12967,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,48,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-12968,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,75,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-12969,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,76,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-12970,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,50,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12971,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,61,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-12972,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,White,Europe,TNBC,Stage I,Control,Responder
P-12973,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,51,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-12974,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,45,Female,Asian,North America,HER2+,Stage III,Experimental,Non-Responder
P-12975,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,Asian,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-12976,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,52,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-12977,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-12978,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,33,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-12979,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-12980,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,48,Female,White,Europe,HER2+,Stage I,Control,Non-Responder
P-12981,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,50,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-12982,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,61,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12983,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,33,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-12984,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,60,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-12985,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,49,Female,Asian,Latin America,HR+/HER2-,Stage III,Control,Responder
P-12986,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,77,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-12987,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,42,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-12988,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,57,Female,Asian,Europe,HER2+,Stage III,Experimental,Responder
P-12989,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,56,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-12990,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-12991,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,77,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-12992,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,42,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-12993,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,63,Female,White,Europe,TNBC,Stage I,Control,Responder
P-12994,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-12995,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,69,Female,Asian,Europe,HER2+,Stage II,Control,Responder
P-12996,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,62,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-12997,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,66,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-12998,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,64,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-12999,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,60,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13000,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,44,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13001,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,67,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13002,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,58,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13003,NCT05583981,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,Ohio State University Comprehensive Cancer Center,58,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-13004,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,71,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-13005,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13006,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13007,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13008,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,50,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13009,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,69,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13010,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,35,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13011,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,38,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13012,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13013,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,51,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13014,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,50,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13015,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,59,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13016,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13017,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,63,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13018,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,67,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Responder
P-13019,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,76,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13020,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,58,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13021,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,81,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13022,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,55,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13023,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,56,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13024,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,70,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13025,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,70,Female,White,Latin America,HER2+,Stage III,Control,Non-Responder
P-13026,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13027,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,53,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-13028,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,45,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13029,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,38,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13030,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,58,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13031,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,59,Female,White,Europe,HER2+,Stage I,Control,Non-Responder
P-13032,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,58,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13033,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,60,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13034,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13035,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13036,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,47,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13037,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,59,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13038,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,58,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-13039,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,44,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-13040,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,69,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13041,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,44,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13042,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,41,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13043,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13044,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,62,Female,Black/African American,North America,HER2+,Stage I,Control,Non-Responder
P-13045,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,39,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13046,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13047,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,58,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-13048,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,69,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13049,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13050,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,63,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13051,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,74,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13052,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,63,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13053,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,45,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13054,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,75,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13055,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,74,Female,White,Europe,TNBC,Stage I,Control,Responder
P-13056,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-13057,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13058,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,Asian,North America,HR+/HER2+,Stage I,Experimental,Responder
P-13059,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,66,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-13060,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,63,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13061,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13062,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,61,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13063,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,65,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13064,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13065,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13066,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,61,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-13067,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,38,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13068,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,43,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13069,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13070,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13071,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-13072,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,55,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13073,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,76,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13074,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,62,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13075,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,29,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13076,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,77,Female,White,Latin America,HR+/HER2-,Stage III,Control,Responder
P-13077,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-13078,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,41,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13079,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,49,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-13080,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,49,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13081,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13082,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,68,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13083,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,67,Female,Hispanic/Latino,North America,TNBC,Stage I,Control,Non-Responder
P-13084,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,47,Female,Asian,Europe,TNBC,Stage II,Experimental,Non-Responder
P-13085,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,81,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13086,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,37,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13087,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,69,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13088,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,43,Female,White,Asia-Pacific,HER2+,Stage I,Control,Non-Responder
P-13089,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,60,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13090,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,65,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13091,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,57,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-13092,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,64,Female,White,Europe,HER2+,Stage I,Control,Non-Responder
P-13093,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,81,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13094,NCT00543764,Intraoperative Pathway in DIEP Flap Breast Reconstruction,Beth Israel Deaconess Medical Center,67,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13095,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,59,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13096,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,73,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13097,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,50,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13098,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,53,Female,White,Europe,HER2+,Stage I,Experimental,Non-Responder
P-13099,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,49,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13100,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13101,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13102,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,76,Female,Asian,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13103,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,40,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13104,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13105,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,75,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13106,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,68,Female,Black/African American,North America,HR+/HER2+,Stage II,Control,Responder
P-13107,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,67,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13108,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,89,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13109,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,51,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13110,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,77,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13111,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,63,Female,Black/African American,Europe,HER2+,Stage III,Control,Non-Responder
P-13112,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,43,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-13113,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,56,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13114,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,56,Female,Black/African American,Europe,HER2+,Stage II,Control,Responder
P-13115,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,64,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13116,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,71,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13117,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,63,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13118,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,66,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-13119,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,57,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-13120,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,61,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-13121,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,68,Female,White,North America,HER2+,Stage III,Control,Responder
P-13122,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,67,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-13123,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,50,Female,Black/African American,North America,HER2+,Stage II,Control,Non-Responder
P-13124,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,26,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-13125,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-13126,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13127,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,63,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13128,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,44,Female,Other,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13129,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,70,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13130,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,39,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13131,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,67,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13132,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,76,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-13133,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,49,Female,Black/African American,North America,HER2+,Stage III,Control,Responder
P-13134,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,62,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13135,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,41,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-13136,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,59,Female,White,Latin America,HER2+,Stage II,Experimental,Responder
P-13137,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13138,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,49,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13139,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,40,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13140,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,68,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-13141,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13142,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,70,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13143,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,74,Female,Black/African American,North America,HER2+,Stage III,Control,Non-Responder
P-13144,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,59,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13145,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13146,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,57,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13147,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,43,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13148,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,77,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-13149,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,59,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13150,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,82,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13151,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,51,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-13152,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,31,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13153,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13154,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,50,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13155,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,48,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Responder
P-13156,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,43,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13157,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,43,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13158,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,47,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13159,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,28,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13160,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13161,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,69,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13162,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,78,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13163,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,56,Female,Hispanic/Latino,Europe,HER2+,Stage I,Control,Responder
P-13164,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,45,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13165,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,57,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13166,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,66,Female,Asian,North America,TNBC,Stage II,Experimental,Responder
P-13167,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,61,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-13168,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,71,Male,White,Europe,HR+/HER2+,Stage III,Experimental,Non-Responder
P-13169,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,50,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Responder
P-13170,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,40,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13171,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,69,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13172,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,47,Male,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13173,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,57,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13174,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,67,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13175,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,64,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13176,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,45,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13177,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,34,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13178,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,55,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-13179,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,70,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13180,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,48,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-13181,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,56,Female,Asian,Europe,HR+/HER2+,Stage I,Control,Responder
P-13182,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,46,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13183,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13184,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,41,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-13185,NCT02597452,Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner,University of Pennsylvania,53,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13186,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13187,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,51,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13188,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,59,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13189,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13190,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,44,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13191,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,40,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-13192,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,31,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13193,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13194,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,60,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13195,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-13196,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,81,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13197,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,69,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13198,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,36,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13199,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,78,Female,White,Europe,HER2+,Stage II,Control,Responder
P-13200,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,White,Europe,HER2+,Stage III,Control,Responder
P-13201,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,Black/African American,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Responder
P-13202,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,47,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13203,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13204,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,58,Female,Other,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13205,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,47,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13206,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,54,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13207,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,52,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13208,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,78,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13209,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,65,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13210,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-13211,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,46,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13212,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13213,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,72,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13214,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13215,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,47,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13216,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,64,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13217,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,38,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13218,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,83,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-13219,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13220,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,47,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13221,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,67,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Responder
P-13222,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,48,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13223,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,83,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage II,Experimental,Non-Responder
P-13224,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,32,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13225,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,68,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-13226,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,49,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-13227,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,70,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13228,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,49,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-13229,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,72,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-13230,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,Black/African American,Europe,HR+/HER2+,Stage I,Control,Responder
P-13231,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,72,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13232,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,31,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13233,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,79,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13234,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,41,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13235,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,41,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-13236,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,46,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13237,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,64,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-13238,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,68,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-13239,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13240,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,47,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-13241,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13242,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13243,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,65,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-13244,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,51,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13245,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,59,Female,White,Asia-Pacific,TNBC,Stage I,Experimental,Non-Responder
P-13246,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13247,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,39,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13248,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,54,Female,Other,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13249,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,61,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13250,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13251,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,46,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13252,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,57,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13253,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13254,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13255,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,64,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13256,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,50,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13257,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,48,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13258,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13259,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,71,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13260,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,37,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13261,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,25,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13262,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,44,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13263,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13264,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,49,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13265,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,51,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13266,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,56,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13267,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,69,Female,White,Europe,HER2+,Stage III,Control,Responder
P-13268,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,60,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13269,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,65,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-13270,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,43,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13271,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,68,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13272,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,73,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-13273,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,53,Female,Asian,Europe,HER2+,Stage III,Experimental,Non-Responder
P-13274,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,54,Female,Other,Europe,HER2+,Stage II,Experimental,Responder
P-13275,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,32,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-13276,NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin ) as Adjuvant for Breast Cancer,Centre Francois Baclesse,59,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13277,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Female,Asian,Asia-Pacific,TNBC,Stage I,Control,Responder
P-13278,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,65,Female,White,Asia-Pacific,HER2+,Stage I,Control,Responder
P-13279,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13280,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,70,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13281,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,43,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13282,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,68,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13283,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13284,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13285,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13286,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13287,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,59,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-13288,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,25,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13289,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-13290,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,57,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-13291,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13292,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,54,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13293,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13294,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,65,Female,White,North America,TNBC,Stage II,Control,Responder
P-13295,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,77,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13296,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,56,Female,Asian,Europe,HER2+,Stage III,Experimental,Responder
P-13297,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,36,Female,Asian,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13298,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,45,Female,Asian,Europe,TNBC,Stage III,Experimental,Non-Responder
P-13299,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,71,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-13300,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,49,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-13301,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,66,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13302,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,63,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13303,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,39,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-13304,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,59,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-13305,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,44,Female,Asian,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-13306,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13307,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,46,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13308,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,62,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13309,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13310,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,60,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13311,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,62,Female,Hispanic/Latino,North America,TNBC,Stage II,Experimental,Non-Responder
P-13312,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-13313,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,49,Female,Hispanic/Latino,North America,HR+/HER2+,Stage III,Experimental,Responder
P-13314,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,43,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13315,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,78,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13316,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,79,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-13317,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,63,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13318,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,63,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13319,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,63,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13320,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,41,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13321,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13322,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,60,Female,Black/African American,North America,HR+/HER2+,Stage II,Experimental,Responder
P-13323,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13324,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,65,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13325,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,42,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13326,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,51,Female,White,North America,TNBC,Stage III,Control,Responder
P-13327,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13328,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,37,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13329,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,54,Female,Black/African American,Latin America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13330,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,59,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13331,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13332,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,69,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13333,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,42,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13334,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,47,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Experimental,Non-Responder
P-13335,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,90,Female,White,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-13336,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-13337,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,71,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13338,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,44,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13339,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,42,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13340,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13341,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,90,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13342,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,52,Female,Other,North America,HER2+,Stage I,Control,Non-Responder
P-13343,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Male,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13344,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,67,Female,Asian,Europe,HER2+,Stage III,Experimental,Responder
P-13345,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,58,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13346,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13347,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13348,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,70,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13349,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13350,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,42,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13351,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,70,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13352,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,64,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13353,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,48,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13354,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,61,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13355,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,66,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13356,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13357,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,71,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13358,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,65,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13359,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,75,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13360,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,69,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-13361,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,59,Female,Asian,Latin America,HR+/HER2-,Stage II,Control,Responder
P-13362,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,57,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13363,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,58,Female,Asian,North America,HER2+,Stage II,Control,Responder
P-13364,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,73,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13365,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,40,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13366,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,63,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13367,NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",University of Washington,53,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13368,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13369,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",52,Male,White,North America,HER2+,Stage II,Control,Non-Responder
P-13370,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",52,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13371,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",42,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13372,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",48,Female,White,Europe,TNBC,Stage I,Control,Non-Responder
P-13373,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",46,Female,Hispanic/Latino,Europe,TNBC,Stage III,Control,Responder
P-13374,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",62,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-13375,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",55,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13376,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",55,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13377,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",75,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13378,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",46,Female,Other,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13379,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",61,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-13380,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",65,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-13381,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",64,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-13382,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",78,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Responder
P-13383,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",69,Female,White,Latin America,HER2+,Stage I,Experimental,Responder
P-13384,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",50,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-13385,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",59,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13386,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",57,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-13387,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",78,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13388,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",67,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13389,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",64,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13390,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",74,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-13391,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",59,Female,White,Europe,TNBC,Stage II,Control,Responder
P-13392,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",59,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-13393,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",59,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13394,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",76,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13395,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",41,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13396,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",56,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13397,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",56,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13398,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",73,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13399,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",55,Female,White,North America,HR+/HER2+,Stage II,Control,Responder
P-13400,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",42,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13401,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",57,Female,White,Europe,HER2+,Stage I,Experimental,Non-Responder
P-13402,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",63,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13403,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",60,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13404,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",40,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13405,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",48,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-13406,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",69,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13407,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",49,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13408,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",69,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-13409,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",46,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13410,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",47,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13411,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13412,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",73,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13413,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",57,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-13414,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",67,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-13415,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13416,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",56,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-13417,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13418,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",64,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-13419,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",58,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13420,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",47,Female,Asian,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-13421,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13422,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13423,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",49,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13424,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",50,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13425,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13426,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",44,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13427,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",69,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13428,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",61,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13429,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",49,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13430,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",55,Female,White,Asia-Pacific,TNBC,Stage II,Control,Responder
P-13431,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",48,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13432,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",73,Female,Asian,North America,TNBC,Stage III,Control,Non-Responder
P-13433,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",55,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-13434,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",66,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13435,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13436,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",62,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13437,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",57,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13438,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",39,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13439,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",49,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13440,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",40,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13441,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",61,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-13442,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",54,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13443,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",66,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13444,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",62,Male,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-13445,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",49,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13446,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",53,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13447,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",81,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-13448,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13449,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",64,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13450,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13451,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",46,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-13452,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",52,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-13453,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",69,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13454,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",71,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13455,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13456,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",72,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-13457,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",47,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13458,NCT00193076,"Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer","SCRI Development Innovations, LLC",72,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-13459,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),39,Female,Hispanic/Latino,North America,TNBC,Stage I,Control,Responder
P-13460,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),54,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13461,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),72,Female,Hispanic/Latino,Latin America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13462,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13463,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),40,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13464,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13465,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,Asian,Europe,HER2+,Stage II,Experimental,Non-Responder
P-13466,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13467,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),70,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13468,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13469,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Black/African American,North America,TNBC,Stage I,Experimental,Non-Responder
P-13470,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-13471,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),49,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-13472,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),36,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13473,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),64,Female,Asian,Latin America,TNBC,Stage II,Control,Non-Responder
P-13474,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13475,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-13476,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13477,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),75,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13478,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),48,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13479,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13480,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),69,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13481,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),58,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13482,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),38,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13483,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),59,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13484,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),52,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13485,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),55,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-13486,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13487,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,White,Asia-Pacific,TNBC,Stage II,Control,Responder
P-13488,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),58,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13489,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13490,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,Asian,North America,TNBC,Stage II,Experimental,Responder
P-13491,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),53,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-13492,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),68,Female,Asian,Europe,HER2+,Stage III,Control,Responder
P-13493,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),54,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13494,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),30,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13495,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13496,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),58,Female,Hispanic/Latino,North America,TNBC,Stage III,Experimental,Responder
P-13497,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),49,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13498,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),34,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13499,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),63,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-13500,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13501,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),59,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13502,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13503,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),70,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-13504,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),42,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13505,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),33,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Responder
P-13506,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),69,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13507,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13508,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),55,Female,White,North America,HR+/HER2+,Stage III,Experimental,Responder
P-13509,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,White,Europe,HR+/HER2+,Stage III,Control,Responder
P-13510,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),90,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13511,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13512,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),56,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13513,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13514,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13515,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13516,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),50,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13517,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),45,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13518,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),58,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13519,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),59,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-13520,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),66,Female,Other,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-13521,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),68,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13522,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13523,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-13524,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13525,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),39,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13526,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),63,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13527,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),41,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13528,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),62,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13529,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13530,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13531,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),42,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13532,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,Asian,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13533,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13534,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),57,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-13535,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),42,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13536,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),52,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13537,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),49,Female,White,Europe,TNBC,Stage II,Control,Responder
P-13538,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),71,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13539,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13540,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),46,Female,White,Asia-Pacific,HER2+,Stage I,Control,Non-Responder
P-13541,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),40,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13542,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),63,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13543,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),65,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-13544,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),68,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-13545,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),59,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13546,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),61,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13547,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),36,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13548,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),51,Female,Black/African American,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-13549,NCT00020332,Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer,National Cancer Institute (NCI),87,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13550,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,35,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage II,Control,Responder
P-13551,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,43,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13552,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,55,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-13553,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,27,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-13554,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,67,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13555,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13556,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,69,Female,Other,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13557,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,81,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13558,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,71,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13559,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,52,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13560,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,82,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-13561,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,64,Female,Other,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13562,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,48,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13563,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,43,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13564,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13565,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,52,Female,Other,Europe,HR+/HER2+,Stage II,Control,Responder
P-13566,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,71,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13567,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,48,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13568,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,43,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13569,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,31,Female,White,North America,HR+/HER2+,Stage III,Control,Responder
P-13570,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,58,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-13571,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,55,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13572,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,42,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Responder
P-13573,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,63,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13574,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,60,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13575,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,65,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13576,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,64,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13577,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,71,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13578,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,56,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13579,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13580,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,52,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-13581,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,65,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Responder
P-13582,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,75,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13583,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,62,Female,Hispanic/Latino,Europe,HER2+,Stage I,Experimental,Non-Responder
P-13584,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,39,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13585,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,49,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13586,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,42,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13587,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,42,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13588,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,51,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-13589,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,56,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13590,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,83,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-13591,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13592,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13593,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13594,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,63,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13595,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13596,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,59,Female,Black/African American,Europe,TNBC,Stage III,Control,Non-Responder
P-13597,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,61,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13598,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,75,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13599,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,58,Female,Black/African American,North America,HER2+,Stage III,Experimental,Non-Responder
P-13600,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,61,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13601,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,65,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13602,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,60,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13603,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,70,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13604,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,45,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-13605,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,68,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13606,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13607,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,75,Female,Other,North America,TNBC,Stage II,Experimental,Responder
P-13608,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,53,Female,Black/African American,North America,TNBC,Stage I,Control,Non-Responder
P-13609,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,71,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-13610,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13611,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,46,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13612,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13613,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,60,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-13614,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,38,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13615,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,54,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13616,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,70,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-13617,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,34,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-13618,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,35,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13619,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,67,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13620,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,77,Female,White,Latin America,HER2+,Stage I,Control,Non-Responder
P-13621,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,58,Female,Other,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13622,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,45,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-13623,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,34,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13624,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,57,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13625,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,65,Female,White,Latin America,HR+/HER2-,Stage III,Control,Responder
P-13626,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,70,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-13627,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,53,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13628,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,38,Female,Asian,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13629,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13630,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,62,Female,White,North America,HER2+,Stage II,Control,Responder
P-13631,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,45,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13632,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,66,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13633,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,74,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13634,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,62,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-13635,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,67,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13636,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13637,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,63,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-13638,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,68,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13639,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,41,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-13640,NCT00874458,MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ,Centre Antoine Lacassagne,27,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13641,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,65,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13642,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,65,Female,White,Latin America,HR+/HER2-,Stage II,Control,Responder
P-13643,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,42,Male,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13644,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,46,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-13645,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,74,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-13646,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,70,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13647,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,70,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13648,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13649,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,60,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13650,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13651,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,41,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13652,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13653,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,37,Female,Asian,North America,HER2+,Stage II,Control,Responder
P-13654,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,82,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13655,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,90,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-13656,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,54,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13657,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,63,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13658,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,78,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-13659,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13660,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,52,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-13661,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,51,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13662,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,51,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13663,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,54,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13664,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,61,Female,White,North America,TNBC,Stage I,Control,Responder
P-13665,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,62,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13666,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,67,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13667,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13668,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,50,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-13669,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,64,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13670,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,57,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13671,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,63,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-13672,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,64,Female,Other,North America,HR+/HER2-,Stage III,Control,Responder
P-13673,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Control,Responder
P-13674,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,71,Female,Black/African American,Europe,HER2+,Stage I,Experimental,Non-Responder
P-13675,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,73,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13676,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,57,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13677,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13678,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,62,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13679,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,51,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13680,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,54,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-13681,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,Hispanic/Latino,North America,TNBC,Stage II,Experimental,Non-Responder
P-13682,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,57,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-13683,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-13684,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Male,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13685,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,53,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13686,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,65,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13687,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,55,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13688,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,69,Female,Other,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13689,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13690,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,83,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13691,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,49,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-13692,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,64,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13693,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,Other,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-13694,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,73,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13695,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,67,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13696,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,34,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13697,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13698,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,46,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-13699,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,73,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13700,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,62,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13701,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,68,Female,Asian,North America,HER2+,Stage III,Control,Non-Responder
P-13702,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,49,Female,Hispanic/Latino,Europe,TNBC,Stage II,Control,Non-Responder
P-13703,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,59,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13704,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,56,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13705,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13706,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,76,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-13707,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,61,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13708,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,74,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-13709,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,62,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-13710,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13711,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13712,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,63,Female,White,North America,TNBC,Stage III,Control,Responder
P-13713,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,81,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13714,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,59,Female,Other,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13715,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13716,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13717,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,63,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-13718,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13719,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13720,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,58,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13721,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,57,Female,White,Latin America,HR+/HER2-,Stage II,Control,Responder
P-13722,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,59,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13723,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,69,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13724,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13725,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,59,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13726,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,45,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-13727,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,45,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13728,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,55,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13729,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,64,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13730,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,76,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-13731,NCT01587248,Use of Harmonic in Breast Surgery,Aga Khan University,48,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-13732,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,48,Female,Asian,Europe,TNBC,Stage III,Experimental,Responder
P-13733,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,67,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13734,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13735,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,71,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13736,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,61,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-13737,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,74,Female,Asian,Europe,HER2+,Stage II,Control,Responder
P-13738,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,49,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13739,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13740,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,76,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13741,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-13742,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-13743,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,56,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-13744,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,32,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13745,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,62,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13746,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,66,Female,Black/African American,North America,HER2+,Stage I,Experimental,Responder
P-13747,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,61,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13748,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,76,Female,White,Latin America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13749,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,46,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Responder
P-13750,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,74,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13751,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13752,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,86,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-13753,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,42,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13754,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,70,Female,White,North America,HER2+,Stage III,Control,Responder
P-13755,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,60,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-13756,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,77,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13757,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13758,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,41,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13759,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,54,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13760,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,67,Male,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13761,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13762,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,52,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13763,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,57,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-13764,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,76,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13765,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,33,Female,Other,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13766,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,71,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-13767,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13768,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,63,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13769,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,83,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13770,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,33,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13771,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,51,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13772,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,73,Female,Black/African American,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13773,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,60,Female,Asian,Europe,TNBC,Stage II,Control,Responder
P-13774,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,73,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13775,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,57,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-13776,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,47,Female,Hispanic/Latino,North America,HER2+,Stage I,Control,Non-Responder
P-13777,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,45,Female,White,North America,HER2+,Stage II,Control,Responder
P-13778,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,88,Female,White,Europe,HER2+,Stage I,Control,Responder
P-13779,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,40,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13780,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,41,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13781,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13782,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,43,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-13783,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,59,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13784,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,40,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-13785,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,79,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13786,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,49,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-13787,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,27,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-13788,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,61,Female,White,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-13789,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,52,Female,Asian,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13790,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,39,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13791,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13792,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,52,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-13793,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,78,Female,White,Latin America,HR+/HER2-,Stage III,Control,Responder
P-13794,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,38,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13795,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,51,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-13796,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,35,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-13797,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,59,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-13798,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13799,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,60,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13800,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,64,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13801,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,51,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-13802,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,68,Female,Black/African American,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-13803,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,50,Female,Asian,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-13804,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13805,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,60,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-13806,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13807,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,79,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-13808,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,49,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-13809,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,70,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13810,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,77,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13811,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,41,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13812,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,70,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-13813,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,59,Female,Asian,Latin America,HR+/HER2-,Stage I,Experimental,Responder
P-13814,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13815,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,49,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13816,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13817,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13818,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,53,Female,Black/African American,Europe,HER2+,Stage III,Control,Non-Responder
P-13819,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13820,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13821,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,68,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13822,NCT05716958,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",Lunit Inc.,57,Female,Asian,Europe,HER2+,Stage III,Control,Responder
P-13823,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,40,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13824,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,38,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-13825,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13826,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,78,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-13827,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,66,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-13828,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,Asian,Europe,TNBC,Stage II,Experimental,Responder
P-13829,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13830,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,59,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13831,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,76,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13832,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,75,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13833,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,71,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-13834,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,48,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Non-Responder
P-13835,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,58,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-13836,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,63,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13837,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,74,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13838,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,75,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13839,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,60,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-13840,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,56,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13841,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13842,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,53,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13843,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13844,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,56,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13845,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,33,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13846,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,51,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13847,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,59,Female,White,North America,TNBC,Stage III,Control,Responder
P-13848,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,51,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13849,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,65,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-13850,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,61,Male,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13851,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,70,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13852,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,49,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13853,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13854,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,68,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13855,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,59,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-13856,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,54,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13857,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-13858,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,65,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13859,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,41,Female,Black/African American,North America,TNBC,Stage II,Experimental,Non-Responder
P-13860,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13861,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,54,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13862,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13863,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-13864,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,42,Female,Black/African American,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-13865,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,72,Female,Black/African American,Latin America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13866,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,50,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13867,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,74,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-13868,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,52,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13869,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13870,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,65,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-13871,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,68,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13872,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,74,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13873,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,58,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-13874,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,48,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13875,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,72,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13876,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,57,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-13877,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,59,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13878,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,66,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-13879,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13880,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,64,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13881,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,52,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13882,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,49,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-13883,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,67,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13884,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,46,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13885,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13886,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,57,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-13887,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,55,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13888,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,61,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13889,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13890,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13891,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,59,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-13892,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,37,Female,Asian,North America,HR+/HER2+,Stage II,Control,Responder
P-13893,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,63,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13894,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,57,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13895,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,35,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13896,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,50,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13897,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,37,Female,Hispanic/Latino,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-13898,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,36,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-13899,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,69,Female,Hispanic/Latino,North America,HER2+,Stage I,Experimental,Responder
P-13900,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,White,Latin America,HER2+,Stage III,Experimental,Responder
P-13901,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,81,Female,White,Europe,HER2+,Stage I,Experimental,Non-Responder
P-13902,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,62,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13903,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,83,Female,Other,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13904,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,69,Female,Asian,Asia-Pacific,HR+/HER2+,Stage II,Experimental,Responder
P-13905,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,57,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-13906,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13907,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,37,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13908,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,46,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-13909,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,33,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-13910,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,29,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13911,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,56,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13912,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,42,Female,Asian,Europe,HER2+,Stage III,Control,Non-Responder
P-13913,NCT04108117,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,Severance Hospital,48,Female,White,North America,TNBC,Stage I,Control,Non-Responder
P-13914,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,62,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13915,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,48,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13916,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,67,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13917,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,59,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13918,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13919,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,62,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13920,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,52,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13921,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,55,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-13922,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,65,Female,Black/African American,North America,HER2+,Stage I,Experimental,Non-Responder
P-13923,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,57,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-13924,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,87,Female,Black/African American,Latin America,TNBC,Stage III,Control,Non-Responder
P-13925,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,53,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-13926,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,56,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13927,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,60,Female,White,Europe,TNBC,Stage II,Control,Responder
P-13928,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,50,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-13929,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,65,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13930,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,65,Female,Other,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13931,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,44,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13932,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,57,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-13933,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,40,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-13934,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,61,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13935,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13936,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,48,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13937,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,80,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13938,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,68,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13939,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,39,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-13940,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,41,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13941,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,53,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13942,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,70,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-13943,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13944,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,67,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13945,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,65,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13946,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,54,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-13947,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,71,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13948,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-13949,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,69,Female,White,Europe,HER2+,Stage II,Control,Responder
P-13950,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,53,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-13951,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,38,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-13952,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,57,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-13953,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,66,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-13954,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,66,Female,White,Latin America,HER2+,Stage III,Control,Responder
P-13955,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-13956,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,69,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13957,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13958,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,56,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13959,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,61,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-13960,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,59,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-13961,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,74,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-13962,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,66,Female,Black/African American,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-13963,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,47,Male,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13964,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,81,Female,White,North America,HR+/HER2+,Stage I,Control,Non-Responder
P-13965,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,48,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-13966,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,53,Female,Black/African American,North America,TNBC,Stage I,Control,Responder
P-13967,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,55,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-13968,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,40,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13969,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13970,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,73,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13971,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,45,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-13972,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-13973,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,53,Female,Black/African American,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-13974,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,50,Female,Asian,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-13975,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,75,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13976,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,58,Female,White,Latin America,HR+/HER2+,Stage III,Control,Non-Responder
P-13977,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,45,Female,White,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-13978,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-13979,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,74,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-13980,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,84,Female,Black/African American,Latin America,TNBC,Stage III,Control,Responder
P-13981,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,62,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-13982,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,68,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-13983,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,48,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-13984,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,71,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-13985,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,65,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13986,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,69,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-13987,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,90,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13988,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,40,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13989,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,78,Female,Other,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-13990,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,44,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-13991,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,71,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13992,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,43,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-13993,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,76,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-13994,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,69,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-13995,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,35,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-13996,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,64,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-13997,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,62,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-13998,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,70,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-13999,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,81,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14000,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14001,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,39,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14002,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,88,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14003,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,51,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14004,NCT01304251,Effects of Short-term Fasting on Tolerance to Chemotherapy,Leiden University Medical Center,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14005,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,57,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14006,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,Black/African American,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-14007,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,55,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14008,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,61,Female,Black/African American,North America,TNBC,Stage I,Control,Non-Responder
P-14009,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,65,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14010,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,70,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-14011,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,62,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-14012,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14013,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,White,Europe,HR+/HER2+,Stage III,Control,Responder
P-14014,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14015,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14016,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14017,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,42,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-14018,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,55,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14019,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,39,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-14020,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,64,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-14021,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14022,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,81,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14023,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,46,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14024,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,32,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14025,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,34,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14026,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14027,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,44,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14028,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14029,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,45,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage III,Control,Responder
P-14030,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,87,Female,Asian,Europe,TNBC,Stage II,Experimental,Responder
P-14031,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,72,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14032,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,48,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-14033,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,69,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14034,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,40,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14035,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,46,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14036,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,45,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14037,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14038,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,61,Female,Asian,North America,HER2+,Stage III,Experimental,Non-Responder
P-14039,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,50,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-14040,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,48,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14041,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,67,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14042,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14043,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14044,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,54,Female,White,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-14045,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-14046,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14047,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,50,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14048,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,47,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-14049,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,70,Female,Asian,North America,TNBC,Stage III,Experimental,Non-Responder
P-14050,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14051,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,43,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14052,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,67,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-14053,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14054,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,73,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14055,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,Black/African American,North America,HER2+,Stage I,Control,Non-Responder
P-14056,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14057,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,63,Female,White,Europe,TNBC,Stage I,Control,Non-Responder
P-14058,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14059,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,71,Female,White,Europe,HER2+,Stage I,Control,Non-Responder
P-14060,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14061,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14062,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,73,Female,Other,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14063,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,65,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14064,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,66,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14065,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-14066,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,77,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Responder
P-14067,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,52,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14068,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,58,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-14069,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,44,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14070,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,51,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14071,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,70,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-14072,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,50,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14073,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,65,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-14074,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,43,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14075,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,45,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14076,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14077,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,65,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14078,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14079,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,80,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14080,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,63,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14081,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,55,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14082,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,90,Female,Hispanic/Latino,North America,TNBC,Stage III,Experimental,Responder
P-14083,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,55,Female,Hispanic/Latino,Europe,HER2+,Stage II,Control,Non-Responder
P-14084,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,30,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14085,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14086,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,57,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14087,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,74,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14088,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,58,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14089,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14090,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,49,Female,White,Europe,HER2+,Stage III,Experimental,Responder
P-14091,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,56,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14092,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,40,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14093,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,57,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14094,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,62,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14095,NCT00416572,Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer,Carnegie Mellon University,72,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14096,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14097,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,71,Female,White,North America,HER2+,Stage I,Experimental,Responder
P-14098,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,50,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-14099,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,61,Female,Black/African American,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-14100,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,40,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14101,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14102,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,40,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14103,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,77,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-14104,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,51,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14105,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,45,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14106,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,66,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14107,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,66,Female,White,North America,HER2+,Stage III,Control,Responder
P-14108,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,36,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14109,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,49,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14110,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,46,Female,White,Latin America,HER2+,Stage III,Experimental,Non-Responder
P-14111,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,56,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14112,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14113,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,45,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14114,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,71,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14115,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,75,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-14116,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,56,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14117,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,45,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-14118,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,53,Female,White,North America,TNBC,Stage II,Control,Responder
P-14119,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,50,Female,Black/African American,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-14120,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,47,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14121,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,40,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14122,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14123,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,34,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14124,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,74,Female,Other,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14125,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,49,Male,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-14126,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,60,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14127,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,44,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14128,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,62,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14129,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,47,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14130,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,78,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-14131,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14132,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14133,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,90,Female,Black/African American,Latin America,TNBC,Stage II,Control,Responder
P-14134,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,70,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14135,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14136,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14137,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,49,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14138,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,68,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-14139,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,65,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-14140,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,76,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14141,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,44,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14142,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14143,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,53,Female,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14144,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,70,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14145,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14146,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,66,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14147,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,59,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14148,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,65,Female,Asian,Europe,HER2+,Stage II,Control,Responder
P-14149,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14150,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,68,Female,White,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-14151,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14152,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,50,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14153,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,65,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-14154,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,66,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14155,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,63,Female,Black/African American,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-14156,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,58,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14157,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,72,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-14158,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14159,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,85,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14160,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,56,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14161,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,76,Female,White,Latin America,TNBC,Stage III,Control,Non-Responder
P-14162,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,45,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-14163,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,46,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14164,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,28,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14165,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,69,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14166,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14167,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,43,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Control,Responder
P-14168,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14169,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,80,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14170,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,44,Female,Other,North America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-14171,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,45,Female,Asian,Asia-Pacific,HER2+,Stage II,Experimental,Responder
P-14172,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,70,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Responder
P-14173,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,63,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14174,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,59,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-14175,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,64,Female,Black/African American,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14176,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,40,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14177,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,37,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14178,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,59,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-14179,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,36,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14180,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,67,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14181,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,71,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14182,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,73,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14183,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,70,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14184,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,47,Female,Asian,North America,TNBC,Stage III,Experimental,Non-Responder
P-14185,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,63,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14186,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Eisai Inc.,61,Female,White,North America,HER2+,Stage III,Control,Responder
P-14187,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",67,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-14188,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",44,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14189,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",61,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-14190,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",59,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14191,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",80,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14192,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",64,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-14193,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",44,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14194,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",73,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-14195,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",60,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14196,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",35,Female,White,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-14197,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14198,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",69,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14199,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",60,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14200,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",52,Female,Asian,Europe,TNBC,Stage II,Control,Non-Responder
P-14201,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14202,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",60,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14203,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",54,Female,Other,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14204,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",64,Female,Asian,North America,TNBC,Stage II,Experimental,Non-Responder
P-14205,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",58,Female,White,North America,HER2+,Stage III,Control,Responder
P-14206,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",43,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14207,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14208,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",56,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-14209,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",52,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14210,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",40,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14211,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",67,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-14212,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",44,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14213,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",48,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14214,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",51,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14215,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",57,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-14216,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14217,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",56,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14218,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14219,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",44,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14220,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",65,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14221,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",66,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14222,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",61,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14223,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",35,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14224,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",58,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14225,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",40,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14226,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",55,Female,Black/African American,North America,HER2+,Stage I,Experimental,Responder
P-14227,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",71,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14228,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",49,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14229,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",39,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14230,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14231,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",37,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-14232,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",59,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14233,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",77,Female,White,North America,TNBC,Stage II,Control,Responder
P-14234,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14235,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",70,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14236,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",70,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14237,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",67,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-14238,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",62,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14239,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",71,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-14240,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",63,Female,Hispanic/Latino,North America,HER2+,Stage II,Control,Responder
P-14241,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",27,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14242,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",45,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14243,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",60,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14244,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",53,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14245,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",90,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14246,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",63,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-14247,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",43,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14248,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",53,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14249,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",25,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14250,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",66,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14251,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",48,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14252,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",42,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14253,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",41,Male,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14254,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",48,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14255,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",65,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14256,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",50,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14257,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",45,Female,Black/African American,Europe,HER2+,Stage II,Control,Non-Responder
P-14258,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",55,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Responder
P-14259,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",64,Female,White,Latin America,HR+/HER2+,Stage II,Control,Non-Responder
P-14260,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",43,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14261,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",64,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14262,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",40,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14263,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",80,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14264,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",57,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-14265,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",57,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-14266,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",73,Female,Asian,Europe,TNBC,Stage II,Experimental,Non-Responder
P-14267,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",59,Female,White,Asia-Pacific,HR+/HER2+,Stage I,Control,Responder
P-14268,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",36,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14269,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",45,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-14270,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",51,Female,White,North America,HR+/HER2+,Stage III,Experimental,Responder
P-14271,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",47,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-14272,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",70,Female,Other,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14273,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",39,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14274,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",72,Female,White,Latin America,HR+/HER2+,Stage II,Experimental,Responder
P-14275,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",49,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14276,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",43,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14277,NCT03015649,Long Term Use of SAVI SCOUT: Pilot Study,"Envision Healthcare Scientific Intelligence, Inc.",62,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14278,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14279,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14280,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,41,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-14281,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,56,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-14282,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14283,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,67,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14284,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,60,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-14285,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,68,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14286,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,62,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14287,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,67,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14288,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,65,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Responder
P-14289,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,64,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14290,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,70,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14291,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14292,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,44,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14293,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,74,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-14294,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,55,Female,White,North America,HER2+,Stage II,Control,Responder
P-14295,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,25,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14296,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,39,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14297,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,75,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14298,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14299,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14300,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,Asian,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-14301,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,56,Female,Hispanic/Latino,Europe,HER2+,Stage I,Control,Responder
P-14302,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,69,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Responder
P-14303,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,54,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14304,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,67,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14305,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,52,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14306,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,62,Female,Hispanic/Latino,North America,TNBC,Stage II,Experimental,Non-Responder
P-14307,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,69,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14308,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,68,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-14309,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,60,Female,Hispanic/Latino,North America,HR+/HER2+,Stage I,Experimental,Non-Responder
P-14310,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,48,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-14311,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,72,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14312,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,69,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14313,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,55,Female,Asian,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-14314,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,59,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-14315,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,72,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14316,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,52,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14317,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,46,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14318,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14319,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,51,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14320,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,54,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14321,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,45,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14322,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,52,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14323,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,38,Female,White,Europe,TNBC,Stage I,Experimental,Non-Responder
P-14324,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,48,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14325,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,39,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14326,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,58,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14327,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,White,North America,HER2+,Stage II,Control,Responder
P-14328,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,38,Female,White,Europe,HER2+,Stage III,Control,Responder
P-14329,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14330,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,25,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14331,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14332,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,48,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14333,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,76,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-14334,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14335,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,61,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-14336,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,65,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-14337,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,47,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14338,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,White,Europe,TNBC,Stage I,Experimental,Responder
P-14339,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,65,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14340,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,62,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14341,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-14342,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,68,Female,White,North America,HR+/HER2+,Stage III,Control,Responder
P-14343,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,69,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14344,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,71,Female,Hispanic/Latino,Europe,HER2+,Stage III,Control,Non-Responder
P-14345,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,69,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-14346,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,85,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14347,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,43,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14348,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,55,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14349,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14350,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,62,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14351,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,55,Female,Other,Europe,HR+/HER2-,Stage III,Control,Responder
P-14352,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,32,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14353,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,52,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14354,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,59,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14355,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,53,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14356,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,57,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14357,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,57,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14358,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,58,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14359,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,83,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-14360,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,71,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-14361,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,57,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14362,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,59,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-14363,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,64,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14364,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,50,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14365,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,43,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14366,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,63,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14367,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,61,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14368,NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,Maastricht Radiation Oncology,49,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14369,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14370,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,41,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14371,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,64,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-14372,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,49,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-14373,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,55,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14374,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14375,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,49,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-14376,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,40,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14377,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,65,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14378,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,White,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-14379,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,54,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14380,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14381,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,61,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14382,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,51,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14383,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14384,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,74,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14385,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,81,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14386,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,66,Female,Hispanic/Latino,Europe,TNBC,Stage II,Control,Responder
P-14387,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14388,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14389,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-14390,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,79,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14391,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,53,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14392,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14393,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,48,Female,Asian,Europe,HER2+,Stage I,Experimental,Responder
P-14394,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14395,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14396,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,83,Female,White,Europe,HER2+,Stage II,Control,Non-Responder
P-14397,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,48,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14398,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,67,Female,White,Europe,HER2+,Stage III,Control,Responder
P-14399,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,Asian,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14400,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,56,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14401,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,49,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14402,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,45,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14403,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,61,Female,Asian,Europe,HR+/HER2-,Stage I,Control,Responder
P-14404,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14405,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,68,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14406,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,35,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14407,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14408,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,64,Female,Black/African American,Europe,TNBC,Stage II,Control,Non-Responder
P-14409,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,71,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14410,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,54,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14411,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,35,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14412,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,65,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-14413,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,35,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14414,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,52,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-14415,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,50,Female,Hispanic/Latino,North America,HER2+,Stage III,Control,Non-Responder
P-14416,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,87,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14417,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,41,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14418,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,72,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14419,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,43,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14420,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,40,Female,Black/African American,North America,HER2+,Stage III,Control,Responder
P-14421,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,75,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14422,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,56,Female,Other,North America,HR+/HER2-,Stage II,Control,Responder
P-14423,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,51,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14424,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,71,Female,White,Latin America,TNBC,Stage III,Control,Responder
P-14425,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,53,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14426,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,44,Female,Other,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14427,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14428,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14429,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,65,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14430,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14431,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,64,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14432,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,29,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14433,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,Black/African American,Europe,TNBC,Stage I,Control,Responder
P-14434,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,53,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14435,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,51,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14436,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,Hispanic/Latino,Europe,TNBC,Stage III,Experimental,Responder
P-14437,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,54,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-14438,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,56,Female,White,North America,HER2+,Stage III,Control,Non-Responder
P-14439,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,47,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-14440,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,59,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14441,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,67,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-14442,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14443,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,77,Female,White,North America,HER2+,Stage III,Control,Responder
P-14444,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14445,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,45,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14446,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,77,Female,White,North America,HER2+,Stage II,Control,Responder
P-14447,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,56,Female,White,Europe,TNBC,Stage I,Experimental,Responder
P-14448,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14449,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,63,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14450,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,58,Female,Asian,Europe,TNBC,Stage II,Control,Non-Responder
P-14451,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,35,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14452,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,25,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14453,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,61,Female,White,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-14454,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,45,Female,Asian,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14455,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,57,Female,White,Europe,HER2+,Stage III,Control,Responder
P-14456,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,68,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14457,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,50,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-14458,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,55,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-14459,NCT02524548,SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors,National University of Singapore,62,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14460,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,60,Female,Hispanic/Latino,Europe,TNBC,Stage I,Experimental,Responder
P-14461,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,56,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14462,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,38,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14463,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,46,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14464,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,90,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14465,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,61,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14466,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,46,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-14467,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,41,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-14468,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,38,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-14469,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,52,Female,Hispanic/Latino,Europe,TNBC,Stage III,Control,Non-Responder
P-14470,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,60,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14471,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,53,Female,Asian,North America,TNBC,Stage II,Control,Non-Responder
P-14472,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,50,Female,Asian,Europe,HER2+,Stage II,Control,Responder
P-14473,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,38,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14474,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,54,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14475,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,90,Female,White,Asia-Pacific,HER2+,Stage II,Control,Responder
P-14476,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,46,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14477,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,45,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14478,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,62,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-14479,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,64,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14480,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,66,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14481,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,76,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14482,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14483,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,65,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-14484,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,80,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14485,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,64,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14486,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,38,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14487,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14488,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,58,Female,Hispanic/Latino,Europe,HER2+,Stage III,Control,Non-Responder
P-14489,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,80,Female,Asian,Europe,TNBC,Stage III,Control,Non-Responder
P-14490,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,46,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14491,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14492,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14493,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,48,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage II,Control,Non-Responder
P-14494,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,56,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-14495,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,38,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14496,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,71,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14497,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,50,Female,White,Europe,HER2+,Stage I,Experimental,Non-Responder
P-14498,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,54,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14499,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,49,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14500,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,39,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14501,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,51,Female,Asian,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-14502,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,53,Female,Asian,Europe,HR+/HER2+,Stage III,Control,Non-Responder
P-14503,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14504,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,81,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14505,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14506,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,44,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-14507,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,43,Female,White,North America,TNBC,Stage III,Control,Responder
P-14508,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,56,Female,Hispanic/Latino,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14509,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,72,Female,White,North America,TNBC,Stage II,Control,Responder
P-14510,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,69,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14511,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14512,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,41,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-14513,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,67,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14514,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,66,Female,Black/African American,North America,HER2+,Stage I,Experimental,Responder
P-14515,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,51,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14516,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,81,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14517,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,47,Female,White,North America,HER2+,Stage II,Control,Responder
P-14518,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,45,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14519,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,51,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14520,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,53,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14521,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,61,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14522,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,39,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14523,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,61,Female,White,Latin America,HR+/HER2-,Stage I,Experimental,Responder
P-14524,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,54,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14525,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,31,Female,White,Europe,HER2+,Stage III,Control,Responder
P-14526,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,70,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14527,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,57,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14528,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,57,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14529,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,68,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14530,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,57,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14531,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,49,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Responder
P-14532,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,56,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-14533,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14534,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,48,Female,Hispanic/Latino,Europe,HER2+,Stage II,Experimental,Responder
P-14535,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,49,Female,Black/African American,North America,TNBC,Stage III,Experimental,Non-Responder
P-14536,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,46,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14537,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,50,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14538,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,81,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14539,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,52,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14540,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,81,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14541,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,54,Female,Asian,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-14542,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,64,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Non-Responder
P-14543,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,47,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-14544,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14545,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,51,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14546,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,88,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14547,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,64,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage III,Control,Non-Responder
P-14548,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,77,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14549,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,42,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-14550,NCT05882578,Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals,Tigers Running Club,43,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14551,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,51,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14552,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,44,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14553,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,42,Male,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14554,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,77,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14555,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,58,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14556,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,71,Female,Asian,Europe,HR+/HER2+,Stage I,Control,Non-Responder
P-14557,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,66,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14558,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,32,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14559,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,67,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14560,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14561,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,50,Female,Other,North America,HER2+,Stage III,Control,Non-Responder
P-14562,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,59,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14563,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,73,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Responder
P-14564,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,52,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14565,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,52,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14566,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,41,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14567,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,47,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-14568,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,82,Female,Black/African American,North America,HER2+,Stage II,Experimental,Non-Responder
P-14569,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,64,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14570,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,39,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14571,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,53,Female,White,North America,TNBC,Stage II,Experimental,Responder
P-14572,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,62,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14573,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,37,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14574,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,77,Female,White,Asia-Pacific,HR+/HER2+,Stage III,Experimental,Non-Responder
P-14575,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,56,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14576,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,61,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14577,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,53,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14578,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,29,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14579,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,50,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-14580,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,54,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-14581,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,74,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14582,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,78,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14583,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,74,Female,White,North America,HER2+,Stage II,Experimental,Non-Responder
P-14584,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,72,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14585,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,47,Female,Asian,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14586,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,77,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Responder
P-14587,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,58,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14588,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,62,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14589,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,46,Female,Asian,Europe,HER2+,Stage III,Control,Non-Responder
P-14590,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,50,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-14591,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,41,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14592,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,60,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14593,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,68,Female,White,Asia-Pacific,HR+/HER2+,Stage I,Experimental,Non-Responder
P-14594,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,46,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14595,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,62,Female,Black/African American,Europe,TNBC,Stage II,Control,Non-Responder
P-14596,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,75,Female,White,North America,TNBC,Stage I,Control,Non-Responder
P-14597,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,38,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14598,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,44,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14599,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,71,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14600,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,42,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Control,Responder
P-14601,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,66,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14602,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,90,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-14603,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,50,Female,White,Europe,TNBC,Stage I,Control,Responder
P-14604,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,65,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14605,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,71,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14606,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,41,Female,Hispanic/Latino,Europe,TNBC,Stage I,Control,Responder
P-14607,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,55,Female,White,Latin America,TNBC,Stage III,Control,Responder
P-14608,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,63,Female,Hispanic/Latino,North America,TNBC,Stage III,Experimental,Non-Responder
P-14609,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,66,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14610,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,43,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14611,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,69,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14612,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14613,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,49,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14614,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,46,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage III,Experimental,Responder
P-14615,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,50,Female,White,North America,HER2+,Stage III,Control,Responder
P-14616,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,49,Female,White,Latin America,HER2+,Stage II,Control,Non-Responder
P-14617,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,69,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14618,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,72,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14619,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,74,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14620,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,49,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14621,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,71,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-14622,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,66,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14623,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,67,Female,Other,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14624,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,49,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14625,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,62,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14626,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,49,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14627,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14628,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,55,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14629,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,57,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14630,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,41,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14631,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14632,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,70,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14633,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Responder
P-14634,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,53,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14635,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,45,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14636,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,47,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14637,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,82,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14638,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,59,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14639,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,63,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14640,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,53,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14641,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Hoffmann-La Roche,59,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14642,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14643,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,53,Female,White,North America,TNBC,Stage III,Control,Responder
P-14644,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,53,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14645,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,46,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14646,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,79,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14647,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,40,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-14648,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,55,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14649,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,63,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14650,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,42,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14651,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,50,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14652,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,79,Female,Asian,Europe,HR+/HER2+,Stage I,Experimental,Non-Responder
P-14653,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,62,Female,Black/African American,Europe,HER2+,Stage II,Experimental,Non-Responder
P-14654,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,43,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14655,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14656,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,65,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14657,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,55,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-14658,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,43,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14659,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,62,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14660,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,69,Female,White,North America,HER2+,Stage I,Control,Responder
P-14661,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14662,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14663,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14664,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,73,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14665,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14666,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,58,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-14667,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,68,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14668,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,58,Female,White,Latin America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14669,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,49,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14670,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,48,Female,White,North America,HER2+,Stage II,Control,Responder
P-14671,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,57,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14672,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,62,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14673,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,71,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14674,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,56,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-14675,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,35,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14676,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,61,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14677,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,46,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14678,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14679,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,25,Female,Black/African American,Latin America,TNBC,Stage III,Control,Responder
P-14680,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,61,Female,Hispanic/Latino,North America,HER2+,Stage II,Experimental,Non-Responder
P-14681,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,56,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14682,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,47,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14683,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14684,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,57,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14685,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,52,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14686,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,64,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-14687,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,36,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14688,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,51,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-14689,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,83,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-14690,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14691,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14692,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,68,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14693,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-14694,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14695,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14696,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,51,Female,Asian,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14697,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,37,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-14698,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,54,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14699,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,57,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14700,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,57,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14701,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,61,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14702,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,53,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-14703,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,71,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14704,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,50,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-14705,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,57,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14706,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,49,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14707,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,68,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14708,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,58,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-14709,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,77,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14710,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,50,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14711,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,49,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14712,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,59,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-14713,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-14714,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,54,Female,White,North America,HR+/HER2-,Stage III,Control,Responder
P-14715,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,68,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14716,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,35,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14717,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,67,Female,Black/African American,North America,TNBC,Stage II,Experimental,Responder
P-14718,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,69,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14719,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14720,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14721,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,67,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14722,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,37,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14723,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,55,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-14724,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,43,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14725,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,34,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14726,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,49,Female,Black/African American,North America,HER2+,Stage I,Control,Non-Responder
P-14727,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,42,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-14728,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,60,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14729,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,81,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14730,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,54,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-14731,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,51,Female,White,North America,HER2+,Stage I,Control,Non-Responder
P-14732,NCT01216111,Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN),Fudan University,61,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14733,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,65,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-14734,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,53,Female,Asian,Latin America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14735,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,60,Female,Other,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14736,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,56,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14737,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,69,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14738,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,47,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-14739,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,49,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14740,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,34,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14741,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,69,Female,Black/African American,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14742,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,38,Female,Asian,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-14743,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,67,Male,White,Asia-Pacific,TNBC,Stage III,Control,Non-Responder
P-14744,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,58,Female,Other,North America,HER2+,Stage II,Control,Non-Responder
P-14745,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,54,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14746,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-14747,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,69,Female,Black/African American,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-14748,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,66,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-14749,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,71,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14750,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,32,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14751,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,73,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Non-Responder
P-14752,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,65,Female,Asian,Europe,HER2+,Stage III,Control,Responder
P-14753,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,White,Europe,HER2+,Stage II,Control,Responder
P-14754,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,47,Female,Black/African American,Europe,HER2+,Stage II,Control,Responder
P-14755,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,57,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14756,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,84,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14757,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,53,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14758,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14759,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,60,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14760,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,72,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14761,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,61,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14762,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,67,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14763,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,55,Female,White,North America,TNBC,Stage I,Experimental,Responder
P-14764,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,62,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14765,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,67,Female,Asian,Asia-Pacific,HER2+,Stage I,Experimental,Non-Responder
P-14766,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14767,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,61,Female,Black/African American,North America,HR+/HER2+,Stage II,Control,Responder
P-14768,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,63,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14769,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14770,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-14771,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14772,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,42,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14773,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,65,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14774,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,65,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14775,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,48,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14776,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,50,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14777,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,Other,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14778,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,62,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14779,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,61,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14780,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,85,Female,White,North America,TNBC,Stage III,Control,Responder
P-14781,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14782,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,Black/African American,Europe,TNBC,Stage III,Control,Non-Responder
P-14783,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,43,Female,Black/African American,Europe,HER2+,Stage III,Control,Responder
P-14784,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,52,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14785,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,63,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14786,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,53,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14787,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,58,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14788,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,56,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14789,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,76,Female,White,North America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-14790,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,78,Female,White,North America,HER2+,Stage II,Control,Responder
P-14791,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,52,Female,Black/African American,Asia-Pacific,HER2+,Stage I,Experimental,Responder
P-14792,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,55,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-14793,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,63,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14794,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,76,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14795,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,66,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14796,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,38,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14797,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,48,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-14798,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,38,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14799,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,42,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14800,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14801,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,60,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14802,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,55,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14803,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,59,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-14804,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,64,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14805,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,71,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14806,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,62,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-14807,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,44,Female,Black/African American,Asia-Pacific,HER2+,Stage I,Experimental,Responder
P-14808,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,48,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14809,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,57,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14810,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,47,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14811,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,39,Female,Asian,Europe,HER2+,Stage I,Experimental,Responder
P-14812,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,42,Female,Asian,North America,HER2+,Stage III,Control,Non-Responder
P-14813,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,62,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14814,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,61,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14815,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,59,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14816,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,59,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-14817,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,70,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14818,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,73,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14819,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,72,Female,Hispanic/Latino,North America,HR+/HER2+,Stage III,Experimental,Responder
P-14820,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,87,Female,White,Europe,HR+/HER2+,Stage I,Experimental,Responder
P-14821,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,25,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14822,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,58,Female,Hispanic/Latino,North America,TNBC,Stage III,Control,Non-Responder
P-14823,NCT07052734,Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients,Sun Yat-sen University,56,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14824,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,64,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14825,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,46,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-14826,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,65,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14827,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,43,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14828,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,90,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14829,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,50,Female,White,Asia-Pacific,HER2+,Stage II,Control,Responder
P-14830,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,52,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14831,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,58,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14832,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,63,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-14833,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,44,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14834,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,62,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14835,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,40,Female,White,North America,HR+/HER2+,Stage II,Experimental,Responder
P-14836,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,52,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14837,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,47,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14838,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Male,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14839,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14840,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,58,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14841,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,63,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14842,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,36,Female,Other,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-14843,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,79,Female,White,Asia-Pacific,TNBC,Stage II,Experimental,Non-Responder
P-14844,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,57,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14845,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-14846,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,76,Female,White,North America,TNBC,Stage I,Experimental,Non-Responder
P-14847,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,White,Latin America,HER2+,Stage III,Experimental,Non-Responder
P-14848,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,50,Female,Black/African American,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-14849,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,49,Female,White,North America,HR+/HER2+,Stage III,Experimental,Non-Responder
P-14850,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,62,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14851,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,Black/African American,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14852,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,54,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14853,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,41,Female,White,Latin America,HR+/HER2+,Stage II,Experimental,Non-Responder
P-14854,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,57,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14855,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,52,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14856,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,67,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14857,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,41,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14858,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,42,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14859,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14860,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,63,Female,Asian,North America,TNBC,Stage II,Control,Non-Responder
P-14861,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,Asian,North America,HER2+,Stage III,Control,Responder
P-14862,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14863,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,62,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14864,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-14865,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,72,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14866,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-14867,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,46,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14868,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,43,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14869,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,64,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14870,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,49,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14871,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,36,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-14872,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,66,Female,White,Asia-Pacific,TNBC,Stage II,Control,Non-Responder
P-14873,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,39,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-14874,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,51,Female,Asian,North America,HER2+,Stage III,Experimental,Non-Responder
P-14875,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,50,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14876,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,47,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14877,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14878,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,69,Female,Other,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-14879,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,53,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14880,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,37,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14881,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-14882,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,54,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-14883,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14884,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,44,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14885,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,80,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14886,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-14887,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,70,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14888,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,61,Female,Asian,North America,TNBC,Stage III,Experimental,Responder
P-14889,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14890,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,52,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-14891,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,68,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14892,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14893,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,45,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-14894,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,36,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14895,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,53,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14896,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,80,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14897,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,58,Female,Hispanic/Latino,Europe,HER2+,Stage II,Control,Non-Responder
P-14898,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14899,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,59,Female,Hispanic/Latino,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14900,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,46,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14901,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14902,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,43,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14903,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,62,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-14904,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,67,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14905,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,67,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14906,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,88,Female,Asian,North America,TNBC,Stage III,Experimental,Responder
P-14907,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,64,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14908,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,78,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14909,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,56,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Responder
P-14910,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,48,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14911,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,55,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14912,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,57,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14913,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,41,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-14914,NCT00514306,Study of Intermittent OSI-906 Dosing,Astellas Pharma Inc,42,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-14915,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,54,Female,Asian,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14916,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,58,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-14917,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,57,Female,White,North America,HR+/HER2+,Stage I,Experimental,Responder
P-14918,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,61,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14919,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14920,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,Black/African American,Europe,HR+/HER2-,Stage I,Control,Responder
P-14921,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,75,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-14922,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,90,Female,Asian,North America,HR+/HER2-,Stage III,Control,Responder
P-14923,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,67,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14924,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,65,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-14925,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,49,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-14926,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,57,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14927,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,43,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14928,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,52,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14929,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,55,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Responder
P-14930,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,48,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-14931,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,79,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-14932,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14933,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,77,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14934,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,47,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14935,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,65,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14936,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,48,Female,White,Europe,HER2+,Stage III,Experimental,Non-Responder
P-14937,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,66,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14938,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,50,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-14939,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,58,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14940,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,58,Female,Asian,Europe,TNBC,Stage II,Experimental,Non-Responder
P-14941,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,73,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14942,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,58,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14943,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,72,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-14944,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,White,Europe,HER2+,Stage III,Control,Responder
P-14945,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,67,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-14946,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,49,Female,Asian,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-14947,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,31,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-14948,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-14949,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,58,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-14950,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,White,North America,HER2+,Stage III,Control,Responder
P-14951,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,56,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-14952,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,43,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14953,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,49,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-14954,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,41,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-14955,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,57,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-14956,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14957,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14958,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,50,Female,Black/African American,Latin America,TNBC,Stage II,Experimental,Non-Responder
P-14959,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,75,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-14960,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,59,Female,White,Asia-Pacific,TNBC,Stage I,Control,Non-Responder
P-14961,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14962,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,79,Female,White,North America,HR+/HER2-,Stage I,Experimental,Non-Responder
P-14963,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,44,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14964,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14965,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,34,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14966,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,45,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14967,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,53,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14968,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,71,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-14969,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,70,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-14970,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-14971,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,64,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-14972,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,30,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-14973,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,67,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-14974,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,69,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-14975,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,46,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-14976,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,52,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-14977,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,70,Female,White,North America,TNBC,Stage I,Control,Responder
P-14978,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,42,Female,Black/African American,North America,TNBC,Stage III,Experimental,Responder
P-14979,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,57,Female,Asian,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-14980,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,72,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-14981,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,57,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-14982,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,50,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-14983,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,Asian,North America,TNBC,Stage III,Experimental,Non-Responder
P-14984,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,69,Female,Asian,Asia-Pacific,TNBC,Stage II,Control,Responder
P-14985,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,47,Female,White,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-14986,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,72,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-14987,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,46,Female,Black/African American,Europe,TNBC,Stage II,Experimental,Non-Responder
P-14988,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,64,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-14989,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,White,Europe,HER2+,Stage II,Experimental,Responder
P-14990,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,42,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-14991,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,54,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-14992,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,50,Female,Black/African American,North America,TNBC,Stage III,Control,Non-Responder
P-14993,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,69,Female,Asian,Europe,TNBC,Stage III,Control,Non-Responder
P-14994,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,39,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-14995,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,65,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-14996,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,66,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-14997,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,66,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-14998,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-14999,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,55,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15000,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,60,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15001,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,71,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15002,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,52,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15003,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,63,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15004,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,47,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15005,NCT03333785,Randomized Trial of eOncoNote,University of Toronto,51,Female,White,Latin America,HER2+,Stage III,Control,Responder
P-15006,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,54,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-15007,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,26,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15008,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,56,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15009,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,56,Female,Hispanic/Latino,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15010,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,61,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-15011,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15012,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,76,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15013,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,64,Female,Asian,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15014,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,68,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15015,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,67,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-15016,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,53,Female,Black/African American,Latin America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15017,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,73,Female,White,North America,TNBC,Stage II,Control,Responder
P-15018,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,48,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15019,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,74,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15020,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,54,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15021,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,62,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15022,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,85,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-15023,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,54,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15024,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,61,Female,White,Europe,HR+/HER2-,Stage II,Control,Responder
P-15025,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,61,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15026,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,52,Female,Other,North America,HR+/HER2+,Stage I,Control,Responder
P-15027,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,81,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-15028,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,64,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15029,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15030,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,88,Female,White,North America,HER2+,Stage III,Control,Responder
P-15031,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,80,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15032,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,67,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-15033,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,52,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15034,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,71,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-15035,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,64,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-15036,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,57,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-15037,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,53,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-15038,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15039,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,54,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15040,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,Asian,North America,HR+/HER2+,Stage II,Control,Non-Responder
P-15041,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,65,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15042,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,56,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15043,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,41,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15044,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,57,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15045,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,73,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15046,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,61,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-15047,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15048,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,77,Female,White,Europe,TNBC,Stage III,Experimental,Non-Responder
P-15049,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,47,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15050,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,62,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15051,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,39,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15052,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,61,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15053,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,66,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-15054,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,46,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-15055,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,41,Female,White,North America,TNBC,Stage I,Control,Non-Responder
P-15056,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,52,Female,White,Asia-Pacific,HER2+,Stage III,Control,Non-Responder
P-15057,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,56,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15058,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,52,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15059,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,58,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15060,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,67,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15061,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,69,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15062,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,78,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-15063,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,66,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15064,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,53,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-15065,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,46,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15066,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,48,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15067,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,70,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15068,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,48,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15069,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,74,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15070,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15071,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15072,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15073,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,60,Male,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15074,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,72,Female,White,North America,HR+/HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15075,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,66,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15076,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15077,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,64,Female,White,Latin America,HER2+,Stage IV (Metastatic),Control,Responder
P-15078,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,66,Female,White,North America,TNBC,Stage I,Experimental,Non-Responder
P-15079,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,33,Female,White,Europe,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15080,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,64,Female,Asian,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15081,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,42,Female,Black/African American,North America,TNBC,Stage II,Control,Non-Responder
P-15082,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,68,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-15083,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,68,Female,Asian,Europe,HER2+,Stage I,Experimental,Responder
P-15084,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,53,Male,Asian,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-15085,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,52,Female,White,North America,HER2+,Stage I,Experimental,Non-Responder
P-15086,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,76,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2+,Stage II,Experimental,Responder
P-15087,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,59,Female,White,Europe,HER2+,Stage III,Control,Responder
P-15088,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,54,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15089,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,38,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15090,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,66,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15091,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,62,Female,White,North America,HR+/HER2+,Stage III,Control,Responder
P-15092,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,58,Female,White,Europe,HER2+,Stage III,Control,Non-Responder
P-15093,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,71,Female,Asian,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-15094,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,47,Female,White,Europe,HR+/HER2-,Stage I,Control,Responder
P-15095,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,51,Female,Asian,North America,TNBC,Stage III,Control,Non-Responder
P-15096,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Hoffmann-La Roche,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15097,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-15098,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,59,Male,Asian,North America,TNBC,Stage II,Control,Responder
P-15099,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,45,Female,Asian,Europe,HER2+,Stage II,Control,Non-Responder
P-15100,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,44,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15101,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,32,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-15102,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,60,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15103,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,47,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15104,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,60,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15105,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,52,Female,White,Europe,TNBC,Stage I,Control,Non-Responder
P-15106,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,57,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15107,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,61,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-15108,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,54,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-15109,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,52,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15110,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,44,Female,White,Europe,TNBC,Stage III,Experimental,Responder
P-15111,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,54,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15112,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,44,Female,White,North America,HER2+,Stage III,Experimental,Responder
P-15113,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,75,Female,Other,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15114,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,49,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-15115,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,62,Female,Black/African American,North America,TNBC,Stage II,Experimental,Responder
P-15116,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,48,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Responder
P-15117,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,67,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15118,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,44,Female,Black/African American,North America,HER2+,Stage II,Control,Non-Responder
P-15119,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,49,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15120,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,35,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15121,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,67,Female,White,Latin America,HR+/HER2-,Stage II,Control,Responder
P-15122,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15123,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,57,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15124,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,41,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15125,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,50,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage I,Control,Non-Responder
P-15126,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,49,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15127,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,61,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15128,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,58,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15129,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,Hispanic/Latino,North America,TNBC,Stage III,Experimental,Non-Responder
P-15130,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15131,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,48,Female,White,Asia-Pacific,HER2+,Stage II,Experimental,Non-Responder
P-15132,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,71,Female,Black/African American,Europe,HR+/HER2+,Stage II,Experimental,Non-Responder
P-15133,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,35,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15134,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15135,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,White,Latin America,HER2+,Stage II,Control,Non-Responder
P-15136,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,55,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15137,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,64,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15138,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,66,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15139,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,69,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15140,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,68,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage I,Control,Responder
P-15141,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15142,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,50,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15143,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,54,Female,Black/African American,North America,HR+/HER2-,Stage I,Control,Responder
P-15144,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,52,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15145,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15146,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,71,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15147,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,36,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-15148,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,66,Female,Black/African American,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15149,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,46,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15150,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,60,Female,White,Europe,HER2+,Stage II,Control,Responder
P-15151,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15152,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,54,Female,Black/African American,North America,TNBC,Stage II,Experimental,Non-Responder
P-15153,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15154,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15155,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,52,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15156,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,52,Female,White,North America,HER2+,Stage III,Control,Responder
P-15157,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15158,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,61,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15159,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,66,Female,White,North America,TNBC,Stage III,Experimental,Responder
P-15160,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,74,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15161,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,31,Female,White,Asia-Pacific,HER2+,Stage II,Control,Responder
P-15162,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,31,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15163,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,70,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage III,Control,Responder
P-15164,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,60,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-15165,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15166,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,45,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15167,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,61,Female,White,Latin America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15168,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,65,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-15169,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,74,Female,Black/African American,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Responder
P-15170,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,79,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15171,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,54,Female,Asian,Europe,HR+/HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15172,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,36,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Responder
P-15173,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,28,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15174,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,60,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15175,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,48,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15176,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,43,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15177,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,59,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15178,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,56,Female,White,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15179,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,47,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-15180,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,46,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15181,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,53,Female,White,Latin America,TNBC,Stage III,Experimental,Non-Responder
P-15182,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,38,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15183,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,59,Female,White,Europe,TNBC,Stage III,Control,Non-Responder
P-15184,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,44,Female,Hispanic/Latino,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-15185,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,56,Female,Black/African American,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-15186,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,64,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15187,NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,University of Alcala,50,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15188,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,62,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15189,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,45,Female,Asian,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15190,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,50,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15191,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,69,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15192,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,40,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15193,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,59,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15194,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,62,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15195,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,70,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15196,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,70,Female,White,Europe,HER2+,Stage III,Control,Responder
P-15197,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15198,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,67,Female,Other,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15199,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,52,Female,Black/African American,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15200,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,52,Female,Other,North America,HR+/HER2-,Stage I,Control,Responder
P-15201,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,39,Female,Asian,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15202,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,65,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15203,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,42,Female,White,Asia-Pacific,TNBC,Stage III,Experimental,Non-Responder
P-15204,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,68,Female,Other,North America,HER2+,Stage II,Experimental,Responder
P-15205,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,63,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-15206,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,43,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15207,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,34,Female,Black/African American,North America,TNBC,Stage I,Control,Non-Responder
P-15208,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,48,Female,Asian,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15209,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,64,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15210,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,50,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15211,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,37,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15212,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,61,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15213,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,69,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-15214,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,62,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-15215,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,52,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15216,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,53,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15217,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-15218,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,56,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15219,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15220,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,57,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15221,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,73,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15222,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,50,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-15223,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,51,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15224,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,48,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15225,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,63,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15226,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15227,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Female,White,Asia-Pacific,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-15228,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15229,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,33,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15230,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,73,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15231,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,41,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15232,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,76,Female,Black/African American,Latin America,TNBC,Stage II,Control,Responder
P-15233,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,51,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15234,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,68,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15235,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,64,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-15236,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,69,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15237,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,57,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15238,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,67,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15239,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,55,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-15240,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,48,Female,White,Latin America,HER2+,Stage III,Experimental,Responder
P-15241,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,54,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15242,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,53,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Responder
P-15243,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Male,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15244,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,73,Female,Asian,Europe,TNBC,Stage III,Experimental,Non-Responder
P-15245,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,32,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15246,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,72,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15247,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,56,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15248,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,54,Female,Black/African American,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15249,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,67,Female,Hispanic/Latino,North America,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15250,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,61,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Non-Responder
P-15251,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,77,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15252,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,47,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15253,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,65,Female,Hispanic/Latino,Asia-Pacific,TNBC,Stage II,Experimental,Responder
P-15254,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,51,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15255,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,75,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-15256,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,45,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Responder
P-15257,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,49,Female,Asian,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15258,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,76,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15259,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,60,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15260,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,45,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15261,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,35,Female,Asian,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15262,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,74,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15263,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,78,Female,Black/African American,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15264,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,54,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15265,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Female,Asian,Latin America,HR+/HER2-,Stage II,Control,Responder
P-15266,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,74,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15267,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,62,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15268,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,65,Female,Other,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15269,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,48,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Control,Non-Responder
P-15270,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,51,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Non-Responder
P-15271,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,53,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15272,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,51,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15273,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,66,Female,White,Asia-Pacific,HR+/HER2+,Stage II,Control,Non-Responder
P-15274,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,49,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-15275,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,58,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15276,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15277,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,71,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15278,NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Centre Georges Francois Leclerc,77,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15279,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,59,Female,White,Europe,HR+/HER2+,Stage III,Experimental,Responder
P-15280,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,50,Female,White,North America,TNBC,Stage II,Control,Responder
P-15281,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,49,Female,White,Europe,TNBC,Stage I,Experimental,Responder
P-15282,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,73,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15283,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,59,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15284,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,54,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15285,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,55,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-15286,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,75,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-15287,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,44,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Responder
P-15288,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,70,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15289,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,34,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15290,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,44,Female,Black/African American,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15291,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,59,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15292,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,54,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-15293,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,47,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15294,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,69,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15295,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,67,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-15296,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,45,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15297,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,46,Female,White,Latin America,HR+/HER2-,Stage III,Control,Non-Responder
P-15298,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,80,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15299,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,64,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Responder
P-15300,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,48,Female,Asian,North America,HR+/HER2-,Stage I,Experimental,Responder
P-15301,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,53,Female,White,North America,TNBC,Stage III,Control,Responder
P-15302,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,72,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15303,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,64,Female,White,Europe,TNBC,Stage II,Control,Non-Responder
P-15304,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,45,Female,Asian,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15305,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,50,Female,White,North America,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15306,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,42,Female,White,North America,HR+/HER2-,Stage I,Control,Responder
P-15307,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,45,Female,Asian,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-15308,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,43,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15309,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,73,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15310,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,38,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15311,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,54,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15312,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,53,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15313,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,55,Female,Asian,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-15314,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,79,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15315,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,52,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15316,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,64,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15317,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,58,Female,White,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-15318,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,75,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15319,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,51,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15320,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,39,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15321,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,71,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-15322,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,41,Female,Black/African American,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15323,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,67,Female,Asian,North America,HR+/HER2-,Stage II,Control,Responder
P-15324,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,62,Female,Black/African American,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15325,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,55,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15326,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,62,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15327,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,75,Female,Other,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-15328,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,52,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15329,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,39,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15330,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,50,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15331,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,53,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15332,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,56,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15333,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,54,Female,Black/African American,Europe,TNBC,Stage III,Experimental,Responder
P-15334,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,79,Female,Asian,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-15335,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,67,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15336,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,48,Female,Black/African American,Europe,HR+/HER2-,Stage I,Experimental,Responder
P-15337,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,39,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15338,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,78,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15339,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,49,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15340,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,66,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15341,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,45,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-15342,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,66,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15343,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,41,Female,White,Europe,TNBC,Stage II,Experimental,Responder
P-15344,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,58,Female,White,North America,HER2+,Stage II,Control,Non-Responder
P-15345,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,61,Female,Hispanic/Latino,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15346,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,55,Female,Black/African American,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15347,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,62,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15348,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,50,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15349,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,61,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15350,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,67,Female,Asian,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15351,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15352,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,68,Female,Other,Latin America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15353,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,62,Female,White,North America,TNBC,Stage III,Control,Non-Responder
P-15354,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,77,Female,White,North America,HR+/HER2-,Stage I,Control,Non-Responder
P-15355,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,37,Female,Black/African American,North America,HR+/HER2-,Stage II,Control,Responder
P-15356,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,76,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-15357,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,64,Female,Black/African American,North America,HER2+,Stage II,Control,Non-Responder
P-15358,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,49,Female,White,North America,HER2+,Stage II,Experimental,Responder
P-15359,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,48,Female,White,North America,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15360,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,85,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15361,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,50,Female,White,North America,HR+/HER2-,Stage II,Control,Responder
P-15362,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,57,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15363,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,74,Female,White,Latin America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15364,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,63,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15365,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,41,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15366,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,90,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-15367,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,47,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15368,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,61,Female,White,Europe,HER2+,Stage IV (Metastatic),Experimental,Responder
P-15369,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Hospital Universitari de Bellvitge,68,Female,White,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15370,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,55,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Experimental,Non-Responder
P-15371,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,74,Female,White,Asia-Pacific,HER2+,Stage IV (Metastatic),Experimental,Non-Responder
P-15372,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,45,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-15373,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,50,Female,White,North America,TNBC,Stage II,Experimental,Non-Responder
P-15374,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,35,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15375,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,65,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15376,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,68,Female,Hispanic/Latino,North America,HR+/HER2+,Stage III,Experimental,Responder
P-15377,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,43,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Responder
P-15378,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,61,Female,Black/African American,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15379,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,50,Female,White,North America,HR+/HER2-,Stage II,Control,Non-Responder
P-15380,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,61,Female,Asian,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15381,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,49,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15382,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,52,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15383,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,46,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15384,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,White,Europe,HR+/HER2+,Stage II,Control,Non-Responder
P-15385,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,49,Female,Black/African American,North America,HR+/HER2-,Stage IV (Metastatic),Control,Non-Responder
P-15386,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,51,Female,Hispanic/Latino,North America,HR+/HER2-,Stage II,Experimental,Non-Responder
P-15387,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,73,Female,White,North America,HR+/HER2-,Stage III,Control,Non-Responder
P-15388,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,44,Female,Asian,Europe,HR+/HER2+,Stage II,Experimental,Responder
P-15389,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,67,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15390,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,Asian,Asia-Pacific,HR+/HER2-,Stage III,Control,Non-Responder
P-15391,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,68,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15392,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,69,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Experimental,Responder
P-15393,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,43,Female,White,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-15394,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,65,Female,White,North America,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15395,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,54,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15396,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,59,Female,White,Asia-Pacific,HER2+,Stage III,Experimental,Non-Responder
P-15397,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,White,Europe,TNBC,Stage II,Experimental,Non-Responder
P-15398,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,55,Female,White,North America,TNBC,Stage II,Control,Non-Responder
P-15399,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,60,Female,White,Europe,HR+/HER2-,Stage II,Experimental,Responder
P-15400,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,55,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15401,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,40,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15402,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,62,Female,White,Europe,HER2+,Stage II,Experimental,Non-Responder
P-15403,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,60,Female,Hispanic/Latino,Europe,HR+/HER2-,Stage I,Control,Non-Responder
P-15404,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,61,Female,Hispanic/Latino,Europe,HER2+,Stage II,Experimental,Non-Responder
P-15405,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,47,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15406,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,66,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15407,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,67,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15408,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,74,Female,White,Europe,HER2+,Stage III,Control,Responder
P-15409,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,61,Female,White,North America,TNBC,Stage III,Experimental,Non-Responder
P-15410,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,62,Female,White,Asia-Pacific,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15411,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,65,Female,White,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15412,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,66,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15413,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,51,Female,White,Europe,HR+/HER2-,Stage I,Experimental,Non-Responder
P-15414,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,54,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-15415,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,67,Female,Hispanic/Latino,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15416,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,50,Female,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15417,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,64,Female,White,Latin America,HR+/HER2-,Stage III,Experimental,Responder
P-15418,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,40,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15419,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,White,Asia-Pacific,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15420,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,68,Female,Black/African American,North America,HER2+,Stage III,Experimental,Responder
P-15421,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,White,Asia-Pacific,HR+/HER2-,Stage II,Control,Responder
P-15422,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,44,Female,White,Latin America,HR+/HER2-,Stage II,Experimental,Responder
P-15423,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,42,Female,White,North America,HR+/HER2-,Stage I,Experimental,Responder
P-15424,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,64,Female,White,Europe,HR+/HER2-,Stage II,Control,Non-Responder
P-15425,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,69,Female,Black/African American,North America,HR+/HER2-,Stage III,Control,Responder
P-15426,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,64,Male,White,Europe,HR+/HER2-,Stage III,Control,Non-Responder
P-15427,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,53,Female,White,Europe,HER2+,Stage I,Experimental,Responder
P-15428,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,70,Female,White,Asia-Pacific,HR+/HER2-,Stage III,Experimental,Non-Responder
P-15429,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,49,Female,White,North America,TNBC,Stage IV (Metastatic),Experimental,Responder
P-15430,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,75,Female,Hispanic/Latino,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-15431,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,59,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15432,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,55,Female,White,North America,HR+/HER2+,Stage III,Control,Non-Responder
P-15433,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,48,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15434,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,55,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15435,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,31,Female,Hispanic/Latino,North America,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15436,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,54,Female,Black/African American,North America,HR+/HER2+,Stage IV (Metastatic),Control,Responder
P-15437,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,45,Female,Asian,Europe,HR+/HER2-,Stage III,Control,Responder
P-15438,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,43,Female,White,North America,HER2+,Stage III,Experimental,Non-Responder
P-15439,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,70,Female,White,Europe,HR+/HER2-,Stage III,Control,Responder
P-15440,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,38,Female,Asian,Europe,HR+/HER2-,Stage II,Control,Responder
P-15441,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,64,Female,White,Europe,HR+/HER2-,Stage III,Experimental,Responder
P-15442,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,59,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15443,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,51,Female,Black/African American,Latin America,HR+/HER2-,Stage II,Control,Non-Responder
P-15444,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,77,Female,Other,North America,HR+/HER2+,Stage IV (Metastatic),Experimental,Responder
P-15445,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,72,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15446,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,51,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Non-Responder
P-15447,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,52,Female,White,Europe,HR+/HER2-,Stage IV (Metastatic),Experimental,Responder
P-15448,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,74,Female,Asian,North America,TNBC,Stage III,Control,Non-Responder
P-15449,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,36,Female,White,North America,HER2+,Stage IV (Metastatic),Control,Non-Responder
P-15450,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,72,Female,Black/African American,Europe,HER2+,Stage IV (Metastatic),Control,Responder
P-15451,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,48,Female,Asian,North America,HER2+,Stage II,Control,Non-Responder
P-15452,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,54,Female,Other,Europe,TNBC,Stage IV (Metastatic),Control,Non-Responder
P-15453,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,54,Female,White,Asia-Pacific,HR+/HER2-,Stage I,Experimental,Responder
P-15454,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,77,Female,White,North America,HR+/HER2-,Stage II,Experimental,Responder
P-15455,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,64,Female,Black/African American,Europe,HR+/HER2+,Stage I,Experimental,Non-Responder
P-15456,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,Hispanic/Latino,North America,TNBC,Stage II,Experimental,Non-Responder
P-15457,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,48,Female,White,North America,HR+/HER2-,Stage III,Experimental,Responder
P-15458,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,58,Female,White,North America,HR+/HER2-,Stage IV (Metastatic),Control,Responder
P-15459,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,34,Female,White,Europe,HER2+,Stage I,Control,Responder
P-15460,NCT00174434,Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer,Pfizer,69,Female,Hispanic/Latino,Europe,TNBC,Stage IV (Metastatic),Experimental,Responder
